The Natural Products Targeting on Allergic Rhinitis: From Traditional Medicine to Modern Drug Discovery

Suhyun Lim 1,†, Iwah Jeong 1,†, Jonghyeok Cho 1, Chaewon Shin 1, Kwan-II Kim 2, Bum-Sang Shim 1, Seong-Gyu Ko 1,3 and Bonglee Kim 1,3,*

1 College of Korean Medicine, Kyung Hee University, Seoul 02447, Korea; lawinno@khu.ac.kr (S.L.); iwah@khu.ac.kr (I.J.); dkfmaekdnjik@khu.ac.kr (J.C.); name1488@khu.ac.kr (C.S.); eslimbs@khu.ac.kr (B.-S.S.); epiko@khu.ac.kr (S.-G.K.)
2 Division of Allergy, Immune and Respiratory System, Department of Internal Korean Medicine, Kyung Hee University, Seoul 02447, Korea; myhappy78@naver.com
3 Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, Seoul 02447, Korea
* Correspondence: bongleekim@khu.ac.kr; Tel.: +82-2-961-9217
† Both of these authors are co-first authors.

Abstract: More than 500 million people suffer from allergic rhinitis (AR) in the world. Current treatments include oral antihistamines and intranasal corticosteroids; however, they often cause side effects and are unsuitable for long-term exposure. Natural products could work as a feasible alternative, and this study aimed to review the efficacies and mechanisms of natural substances in AR therapies by examining previous literature. Fifty-seven studies were collected and classified into plants, fungi, and minerals decoction; clinical trials were organized separately. The majority of the natural products showed their efficacies by two mechanisms: anti-inflammation regulating diverse mediators and anti-oxidation controlling the activity of nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway stimulated by reactive oxygen species (ROS). The main AR factors modified by natural products included interleukin (IL)-4, IL-5, IL-13, interferon-gamma (IFN-γ), tumor necrosis factor-α (TNF-α), cyclooxygenase 2 (COX-2), and phospho-ERK1/2 (p-ERK1/2). Although further studies are required to verify their efficacies and safeties, natural products can significantly contribute to the treatment of AR.

Keywords: allergic rhinitis; natural products; antioxidants; inflammation; interleukin; nuclear factor kappa-light-chain-enhancer of activated B cells

1. Introduction

Allergic rhinitis (AR), also known as hay fever, is inflammation inside the nose stimulated by specific allergens, usually pollen or dust [1]. Due to its high prevalence and the negative impact on patients’ quality of life, AR is regarded as a major chronic disease. More than 500 million people suffer from AR, and up to 40% of the global population is affected [2]. It is an immunoglobulin E (IgE)-mediated disorder in the nose and triggered by the interaction between specific mast cell IgE antibodies and allergens present in the air. The interaction causes the mast cells to release chemicals that act as inflammatory agents, thus resulting in inflamed marginal tissues [3]. Consequently, it is considered part of a systemic inflammatory process. The symptoms include rhinorrhea, nasal itching, sneezing, and nasal congestion, and are also associated with upper and lower airway membrane disorders: asthma, rhinosinusitis, conjunctivitis, and polyposis [4].

Histamine released from mast cells is the dominant factor of allergic reactions, and the secretion of interleukin (IL)-4 and IL-5 follows, generating T helper cell 2 (Th2) cytokine response. It is, therefore, crucial to control histamine pathways in treating AR. Current therapeutic interventions commonly used are oral antihistamines and intranasal
corticosteroids [5]. Antihistamines block the binding of histamine to the H1 receptor, preventing the release of histamines [6]. Although second-generation antihistamines have fewer side effects, they are still sedating and may provoke psychomotor retardation and reduced academic performance [7,8]. Intranasal corticosteroids control inflammation by regulating mediator release [9]. However, long-term exposure may increase the risk of osteoporosis, fractures, cataracts, hyperglycemia, infection risk, slower wound healing, and headache [10]. Natural products could be plausible options for curing AR, as treatments that cover these adversaries and effectively maintain therapeutic efficacy are in need.

Plant extracts have been used as conventional treatment for thousands of years in many countries, including Korea, Japan, China, etc. [11,12]. Unlike synthetic drugs, they down-regulate harmful side effects and mitigate the damages of various therapy, such as onco-chemotherapy or radiotherapy [13,14]. Furthermore, they are capable of multi-targeting the immune system since they consist of diverse molecules in nature. Many of the previous works of literature have demonstrated the individual efficacy of each product in treating allergic symptoms, but an overall review of these plant extracts is absent. This paper concentrated on plant extracts that have been tested as a remedy for allergic rhinitis and examined their mechanisms, aiming to invigorate the use of natural substances in AR therapies.

2. Pathogenesis of Allergic Rhinitis

2.1. T Helper Cell Differentiation

There are several mechanisms of AR; Th cell differentiation can primarily lead to AR symptoms (Figure 1). Allergens trigger IgE to bind to the high-affinity receptor on the surface of mast cells, and diverse mediators such as histamine, leukotrienes, and cytokines are subsequently released [15–19]. These agents create inflammation mostly in the nasal mucosa, causing mucus secretion, sneezing and sometimes reduce the size of airways by inducing vasodilation of blood vessels. Several mechanisms produce immune responses, thus leading to allergic reactions. IL-4 and IL-12 from the antigen-presenting cell (APC) initiate the manipulation of Th cells. Th cells differentiate from Th0 cells, a common precursor, into Th1, Th2, Th17, or regulatory T (Treg) cells. For Th1 cells to differentiate from Th0 cells, IL-12 activates T-box-expressed-in-T-cells (T-bet) through STAT4 [20]. Th1 cells immunize against pathogens invading into other cells by secreting mainly IL-2, IFN-γ, and TNF-α. Cytokines secreted by Th1, IL-2, IFN-γ, and transforming growth factor (TGF)-β, elicit immunoglobulin G2a (IgG2a) that reduces symptoms. IFN-γ is also responsible for cell-mediated immunity by instigating a macrophagic reaction, hence generating delayed-type hypersensitivity (DTH). IL-4 stimulates the activation of GATA binding protein 3 (GATA3) and signal transducer and activator of transcription 6 (STAT6), the factors related to Th2 cells differentiation, while suppressing T-bet and STAT4. Th2 cells produce IL-4, IL-10, and IL-13 for IgE and IgG1 promotion and IL-5 for eosinophil growth and differentiation. IgE production by B cells is followed by the release of the mediator, histamine, leukotrienes, prostaglandins, and cytokines, by mast cells. The products elicit acute symptoms, whereas the eosinophil is responsible for chronic symptoms. IgG1 from B cells is involved in defense against huge, extracellular pathogens. Substance P (SP) binding to the neurokinin-1 receptor (NK-1R) leads to vasodilation and the release of histamine from mast cells [21–23]. TGF-β and IL-6 together regulate STAT3 and retinoic-related orphan receptors (RoRyt). RoRyt secretes IL-23, which initiates the alteration of Th0 into Th17 cells. Th17 cells are accountable for cell-mediated inflammation and autoimmune diseases induced while protecting the host against extracellular pathogens and fungi. Lastly, Th0 cells are transited to Treg cells by activation of Forkhead box p3 (Foxp3). Treg cells secrete IL-10 and TGF-β, acting on B cells to produce IgG4 and IgA, respectively. IgG4 reduces symptoms, while IgA defends against infection by microorganisms.
2.2. Histamine Receptors

Histamine is released when allergens induce nasal mast cell degranulation, thus releasing mediators into the nasal mucosa [24]. Histamine, converted from histidine by histidine decarboxylase (HDC), mediates allergy and inflammation by activating histamine receptors [25–28]. There are four histamine receptors, but only three are known for their separate roles, mainly conducting the early phase of allergic responses whose symptoms fade within 15–20 min. The histamine H1 receptor (H1R) induces symptoms, such as sneezing, pruritus, rhinorrhea, and nasal blockage by activating nasal nociceptive sensory nerves (5th nerve). The stimulation of sensory nerves causes the release of acetylcholine from nasal parasympathetic nerves and central reflex-dependent bilateral increase, resulting in increased nasal mucus secretion. H1R coupled with G protein Gq/11 activates phospholipase C (PLC), stimulating 1, 4, 5-inositol trisphosphate (IP3) production to induce Ca2+ mobilization and diacylglycerol (DAG), which activates protein kinase C (PKC) [29,30]. PKC activates the transcription factor NF-κB, resulting in augmented transcription of proinflammatory genes. Ca2+ promotes the vasodilation of nasal blood vessels as well [31]. The histamine H2 receptor (H2R), coupled with G5-proteins, mainly leads to nasal blockage. H2R coupled with G5-proteins activates adenylyl cyclase (AC). AC stimulates cyclic adenosine monophosphate (cAMP) production, inducing cAMP-responsive element-binding protein (CREB) [32–34]. cAMP-dependent protein kinase (PKA) signaling inhibits leukotriene synthesis in neutrophils [35]. The histamine H3 receptor (H3R) suppresses substance P release from nasal nociceptive sensory nerves. H3R coupled with Gi/o protein negatively regulates AC; however, it activates mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K), which stimulates the phosphorylation of Akt [36–38]. H3R also promotes IgE-mediated activation of mast cells degranulation [39].

2.3. 5-Lipooxygenase Pathway and Prostaglandin E2 Synthesis-and-Signaling Pathway

The 5-lipooxygenase (LO) pathway and prostaglandin E2 (PGE2) synthesis-and-signaling pathway are related to AR. ROS stimulates the activity of mitogen-activated protein kinase (MAPK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway, thus inducing the expression of COX-2 [40,41]. As a result, PGE2 signals occur through EP1, EP2, EP3, and EP4 [42]. Activation of G protein-coupled receptors EP1–EP4 through binding with PGE2 leads to the regulation of intracellular Ca2+ and cAMP. Activated EP1 and EP3 increase intracellular Ca2+, EP2 and EP4 provoke the cAMP production, while EP3 suppresses it [43]. The dinitrophenyl (DNP) antigen activates immunoreceptor tyrosine activation motifs (ITAM)-Spleen tyrosine kinase (SyK) pathway by
binding to the IgE anti-DNP/FcεRI receptor complex, resulting in degranulation by the activation of PKC [44]. Activated PKC induces the activation of phospholipase A₂, increasing arachidonic acid (AA) bioavailability related to metabolism [45]. AA is converted into 5-hydroperoxy eicosatetraenoic acid (5-HPETE), then leukotriene A₄ (LTA₄), and leukotriene C₄ (LTC₄) subsequently by 5-lipoxygenase (5-Lox). The increase in intracellular calcium results in degranulation. The conversion of AA to 5HPETE, then to LTA₄, is stimulated by 5-Lox and 5-LO-activating protein (FLAP) [46,47]. LTA₄ produces LTC₄, LTD₄, and LTE₄ or transforms into LTB₄. LTC₄, LTD₄, and LTE₄ bind to cysteinyI leukotrienI 1 (CysLT1) receptors, evoking chemotaxis, chemokine expression, and EC proliferation [48,49].

2.4. Immune Response Pathways

Src family tyrosine kinase Lyn activates kinase signaling in B lymphocytes, while caspase-1 mediates secretion of proinflammatory cytokines, resulting in immune responses. B cell receptor (BCR) is composed of membrane-bound Ig and heterodimeric signaling subunit Ig-α/Ig-β [50,51]. When the antigen binds with BCR, Ig-α/β ITAMs are activated and phosphorylated by Lyn, resulting in the activation of Syk. Activated Syk phosphorylates activate Bruton’s tyrosine kinase (BTK) and phospholipase C gamma 2 (PLCγ2). Recruitment of BTK follows. Syk also induces the recruitment and phosphorylation of p85, resulting in the generation of phosphatidylinositol 3, 4, 5-trisphosphate (PIP₃) from phosphatidylinositol 4, 5-trisphosphate (PIP₂). PIP₃ phosphorylates Akt, activating alpha and beta subunits of the IkB kinase (IKK β/α), nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (IκBα), and the p65 NF-κB are phosphorylated by IKK β/α, then degraded and translocated, respectively. Lyn, Syk, and BTK stimulate the phosphorylation and activation of PLCγ2, which hydrolyzes PIP₂, generating IP₃ and DAG. Ca²⁺ mobilization and PKC-β stimulation results in MAPK pathway activation, NF-κB, and the nuclear factor of activated T-cells (NF-AT) nuclear location. Through IL-1β signaling, PKC δ activates NF-κB [52,53]. Pro-caspase-1, apoptosis-associated speck-like protein containing a CARD (ASC), and NLR family pyrin domain containing 3 (NLRP3) are combined to form a complex which activates caspase-1, a factor that activates and releases IL-1β and IL-18 [54].

3. Natural Products That Inhibit Allergic Rhinitis

3.1. Plant-Originated Natural Products

Plant-originated natural products are substances derived from herbs, flowers, trees, etc. They are naturally extracted rather than artificially synthesized. The efficacy of plants containing medical substances is principally descendent from the past, and sometimes they are newly discovered.

3.1.1. In Vitro Studies

There were eighteen in vitro studies of plant-originated natural products (Table 1). The bark of *Albizia lebbeck* is an ingredient of Ayurvedic Kadha, which has been used for treating asthma for more than two thousand years [55]. Propidium Monoazide-treated HeLa cells were administered with 0.1, 1, and 10 µg/mL of *Albizia lebbeck* bark ethanol extract for 24 h. Additionally, histamine-treated HeLa cells were administered with 10 µg/mL of the same extract for 24 h. Both treatments were related to the degradation of IL-4, IL-5, IL-13, H1R, and HDC.

Brazilian green propolis (BGPP), mainly isolated from *Baccharis dracunculifolia* and produced in Southeast Brazil, has been extensively consumed as a dietary supplement. HeLa cells were administered with 25, 75, 100, 125, and 200 µg/mL of BGPP ethanol extract for 3 h [56]. Additionally, RBL-2H3 cells were treated with 25, 75, and 100 µg/mL of BGPP ethanol extract for 3 h. The first experiment degraded levels of H1R mRNA, p-PKCδ, and IL-9, and the second decreased levels of IL-9.

Tani et al. demonstrated Brazilian green propolis ethanol extract prevented nasal obstruction through degradation of IL-5, IL-14, and CysteinyI leukotrienes (CysLTs) [57].
Cry j1-treated peripheral blood mononuclear cells (PBMCs) were treated with 3, 10, and 30 µg/mL of Brazilian green propolis extract for 6 days.

Chrysin (5, 7-dihydroxyflavone) is isolated from propolis, blue passionflower (Passiflora caerulea), vegetables, and fruits [58]. Several studies have reported that chrysin has beneficial effects, including anti-tumor and antioxidant activities. Anti-DNP IgE-sensitized RBL-2H3 cells, phorbol myristate acetate (PMA)/A23187-treated RBL-2H3 cells, and PMA/A23187-treated HMC-1 were administered with 0.1, 1, and 10 µg/mL of Chrysin for 30 min. Chrysin inhibited the mast cell-derived allergic inflammatory reaction by decreasing TNF-α, IL-1β, IL-4, IL-6, caspase-1, and NF-κB levels.

A combination of preparations from Citrus and Cydonia have been commonly used as injections or sprays to treat allergic patients during the past hundred years [59]. *Citrus limon* Burm. f. was stimulated on PBMCs at the amount of 0.01 g/mL for 7 days [60]. PBMCs were obtained from the blood of five grass pollen-allergic donors aged 18–40 and five healthy eligible participants who had no sign of allergic rhinitis. Citrus reduced Th2 pathway activation by ameliorating the level of IFN-γ and down-regulating TNF-α, IL-5 cytokines. By using the same method, *Cydonia oblonga* Mill. was stimulated. Cydonia was mainly concerned with increasing the innate related Th1 pathway activity by the induction of the IFN-γ cytokine.

*Elsholtzia ciliata* (Thunb.) Hyl. is a herb that has been used as a traditional oriental medication for the treatment of fever, headache, diarrhea, and edema [61]. A water extract of *Elsholtzia ciliata* (Thunb.) Hyl. (Labiatae) inhibited mast cell-mediated allergic reactions and treated allergic inflammatory disease. PMACI exposed HMC-1 were treated with 1, 10, and 100 µg/mL of water extract of Elsholtzia ciliate for 30 min. TNF-α, IL-6, IkBα, NF-κB, and phospho-p38 mitogen-activated protein kinases (p-p38 MAPK) were degraded.

Shaha et al. injected 25, 75, 100, 125, and 200 µg/mL of enzyme-treated (protease-degraded) royal jelly (3.5% (E)-10-hydroxy-2-decenoic acid and 0.6% 10-hydroxydecanoic acid) to HeLa cells and RBL-2H3 cells for 12 h [56]. Decreased levels of H1R mRNA, p-PKCδ, and IL-9 were confirmed, suggesting that royal jelly improved allergic nasal symptoms.

*Magnoliae Flos* is an oriental herb commonly used in traditional Chinese and Korean medicine formulations [62]. It has been commonly used as a symptomatic relief to allergic rhinitis, sinusitis, and headache. Kim et al. administered 0.1, 0.3, and 1 mg/mL of FM ethanol extract (FM EtOH) to hANO1-transfected HEK293T cells for 600 s. Additionally, HEK293T and Calu-3 cells were treated with 30, 100, and 300 µg/mL of FM EtOH for 600 s.

Gencydo®, a combination of lemon (*Citrus limon*) juice and aqueous quince (*Cydonia oblonga*) extract has been used traditionally in anthroposophical medicine for treating patients with allergic rhinitis or asthma [63]. DNP-HSA-treated RBL-2H3 were treated with 0.2, 0.4, and 0.8 mg/mL of Gencydo® for 10 min, thus inhibiting the release of histamine and degranulation. Meanwhile, TNF-α/IL-4-exposed human bronchial epithelial cells, PMA/A23187-activated HMC, and granulocyte-macrophage colony-stimulating factor (GM-CSF)-treated human eosinophil granulocytes were treated with 0.2, 0.4, and 0.8 mg/mL of Gencydo® for 24 h. Gencydo® inhibited the release of eotaxin and restrained early and late-phase allergic reactions when injected into human bronchial epithelial cells and HMC, respectively. However, Gencydo® had no impact on the state of GM-CSF-treated human eosinophils.

*Lindera obtusiloba*, a traditional Korean medicine, has been used in the treatment of inflammation and improvement of blood circulation [64]. Herbal infusions of *Lindera obtusiloba* have been used to treat chronic liver disease. PMACI-treated HMC-1, dinitrophenyl-human serum albumin (DNP-HSA)-treated RBL-2H3, and DNP-HSA-treated RPMCs were administered with 0.1, 1, 10, and 100 µg/mL of *Lindera obtusiloba* water extract for 30 min. *Lindera obtusiloba* water extract reduced histamine release and inhibited systemic and local allergic reactions.

Ortho-vanillic acid (2-hydroxy-3-methoxybenzoic acid), isolated from *Amomum xanthioides*, strongly inhibited mast cell-mediated allergic inflammation [65]. RPMCs and ortho-vanillic acid-treated RBL-2H3 cells were injected with 1, 10, and 100 nmol/L of
ortho-vanillic acid for 24 h. Degradation of TNF-α, IL-4, phospho-Lyn (p-Lyn), p-Syk, and p-Akt was involved.

The roots of *Ostericum koreanum* Maxim. (Osterici Radix) have been traditionally used as a herbal medicine to treat colds, headaches, neuralgia, and arthralgia [66]. PMA/A23187-treated RPMCs were administered with 0.2, 0.5, and 1 mg/mL of OR extract for 30 min, while 0.5 and 1 mg/mL of the extract was administered to compound 48/80-treated RPMCs for 15 min. Downregulations in TNF-α, IL-6, p-ERK1/2, p-p38 MAPK, and p-IκBα were shown.

*Perilla frutescens* is a dietary leaf herb that has been used for Chinese medicine, known for its anti-inflammatory activity [67]. Kamei et al. reported that *Perilla*-derived methoxyflavanone prevented passive cutaneous anaphylaxis and allergic rhinitis-like nasal symptoms. *Perilla*-derived methoxyflavanone was treated to anti-DNP IgE-sensitized RBL-2H3 cells. Representative indicators such as p-Akt and intracellular Ca\(^{2+}\) influx were negatively regulated.

Effects and mechanism of 30% ethanol extract powder of *Perilla frutescens* var. acuta Kudo was observed [68]. It was treated to mouse mast cells and mouse eosinophils at a dose of 1 g/kg for 10 days. Additionally, PMACI-exposed HMC-1 was treated with 0.01, 0.1, and 1 mg/mL of EPPF for 1 h. The decoction initiated the degradation of IL-1β, IL-6, TNF-α, COX-2, and NF-κB.

Rosmarinic acid was treated to mouse mast cells and mouse eosinophils at a dose of 4 g/kg for 10 days, and 100 µM was treated to PMACI-exposed HMC-1 for 1 h [68]. The effects of rosmarinic acid were related to the degradation of IL-1β, IL-6, TNF-α, and NF-κB.

*Spinacia oleracea* Linn. extract was orally administered to Hydrogen peroxide-applied SH-SY5Y neuroblastoma cells at a dose of 25 µL/mL for 24 h [69]. Viable cell number recovery related to reduced levels of IL-4, IL-13, and Ig-E was observed.

Treatment of Ze339 at a dose of 3 µg/mg in human nasal epithelial cells from inferior turbinate of patients for 24 h inhibited the recruitment of inflammatory cells, pro-inflammatory cytokine, and chemokine response of viral mimics [70]. Ze339 increased the expression of granulocyte-colony stimulating factor (G-CSF) and decreased the expression of IL-8, chemokine (C-C motif) ligand 3 (CCL-3), IL-6, signal transducer, an activator of transcription 1 (STAT1), STAT3, and STAT6.

### Table 1. In vitro studies—plant-originated natural products.

| Compound/Extract | Source | Experimental Subject | Dose; Duration | Efficacy | Mechanism | Reference |
|------------------|--------|----------------------|----------------|----------|-----------|-----------|
| *Albizia lebbeck* bark ethanol extract | *Albizia lebbeck* | PMA-treated HeLa | 0.1, 1, 10 µg/mL; 24 h | Improvement of allergic nasal symptoms | ↓ H1R, HDC | [55] |
| | | Histamine-treated HeLa | 10 µg/mL; 24 h | | | |
| Brazilian green propolis ethanol extract | *Baccharis dracunculifolia* | TDI-sensitized rats | 40, 80 mg/kg; 3 weeks | Improvement of allergic nasal symptoms | ↓ HIR, p-PKCδ, IL-9, IL-4, IL-5 | [56] |
| | | HeLa | 25, 75, 100, 125, 200 µg/mL; 3 h | | ↓ HIR, p-PKCδ, IL-9 | |
| | | RBL-2H3 | 25, 75, 100 µg/mL; 3 h | | | |
| Brazilian green propolis ethanol extract | *Baccharis dracunculifolia* | Cry j1-treated PBMCs | 3, 10, 30 µg/mL; 6 days | Prevention of the nasal obstruction | ↓ IL-5, IL-13 | [57] |
| | | Cry j1-treated peripheral leukocytes from allergic human | 3, 10, 30, 100 µg/mL; 6 days | | ↓ CysLTs | |
| Chrysin (5,7-dihydroxyflavone) | *Passiflora caerulea* | (Anti-DNP IgE)-sensitized RBL-2H3 | 0.1, 1, 10 µg/mL; 30 min | Inhibition of mast cell-derived allergic inflammatory reactions | ↓ TNF-α, IL-1β, IL-4, IL-6, caspase-1, NF-κB | [58] |
| | | PMA/A23187-treated RBL-2H3 | | | | |
| | | PMA/A23187-treated HMC-1 | | | | |
| Compound/Extract | Source | Experimental Subject | Dose; Duration | Efficacy | Mechanism | Reference |
|------------------|--------|----------------------|----------------|----------|-----------|-----------|
| *Citrus limon* Burm. f. | *Citrus limon* (L.) Burm. f. | PBMCs from five grass pollen-allergic human | 0.01 g/mL; 7 days | Reduction of allergic responses | ↑ IFN-γ, ↓ TNF-α, IL-5 | [60] |
| *Cydonia oblonga* Mill. | *Cydonia oblonga* Mill. | PBMCs from five grass pollen-allergic human | 0.01 g/mL; 7 days | Reduction of allergic responses | ↑ IFN-γ | [60] |
| *Elsholtzia ciliata* (Thunb.) Hyl. | *Elsholtzia ciliata* (Thunb.) Hyl. | PMACI-exposed HMC-1 | 1, 10, 100 µg/mL; 30 min | Inhibition of mast cell-mediated allergic reactions | ↑ IFN-γ | [61] |
| Enzyme-treated (protease-degraded) Royal Jelly | *Apis cerana* Fabricius | RBL-2H3 | 25, 75, 100 µg/mL; 3 h | Improvement of allergic nasal symptoms | ↓ H1R, p-PKCδ, IL-9 | [56] |
| *Magnoliae Flos* ethanol extract | *Magnoliae Flos* | kAN01-transfected HEK293T | 0.1, 0.3, 1 mg/mL; 600 s | Prevention of allergic rhinitis | ↓ IKBa, ↓ TNF-α, IL-6, NF-kB, p-p38 MAPK | [62] |
| *Gencydo®* | *Citrus limon*, *Cydonia oblonga* | (DNP-4-HSA)-treated RBL-2H3 | 0.2, 0.4, 0.8 mg/mL; 10 min | Inhibition of the release of histamine and degranulation | ↓ IL-8, TNF-α | [63] |
| *Lindera obtusiloba* water extract | *Lindera obtusiloba* | PMACI-treated HMC-1 | 0.1, 1, 10, 100 µg/mL; 30 min | Reduction of histamine release | ↑ 1xβδ, ↓ TNF-α, IL-6, NFκB, histamine | [64] |
| Ortho-vanillic acid | *Amomum xanthioides* | RPMCs | 1, 10, 100 nmol/L; 24 h | Suppression of the mast cell-mediated allergic inflammatory response | ↓ TNF-α, IL-4, p-Lyn, p-Syk, p-Akt | [65] |
| *Ostericum koreanum* root methanol extract | | RPMCs | 1, 10, 100 nmol/L; 24 h | Suppression of histamine release | ↓ TNF-α, IL-6, p-ERK1/2, p-p38 MAPK, p-1xβδ | [66] |
| Perilla-derived methoxyflavanone | *Perilla frutescens* | (Anti-DNP IgE)-sensitized RBL-2H3 | 0.2–0.5, 1 mg/mL; 30 min | Attenuation of disease progression as determined by nasal symptoms and histological changes of the nasal mucosa | ↓ TNF-α, IL-6, NFκB, histamine | [67] |
Table 1. Cont.

| Compound/Extract                     | Source                                      | Experimental Subject                          | Dose; Duration | Efficacy                                                       | Mechanism                                                                 | Reference |
|--------------------------------------|---------------------------------------------|-----------------------------------------------|----------------|----------------------------------------------------------------|---------------------------------------------------------------------------|-----------|
| *Perilla frutescens* var. acuta Kudo | 30% ethanol extract powder                  | Mouse mast cells                              | 1 g/kg; 10 days| Amelioration of allergic inflammatory reactions                | ↓ IL-1β, IL-6, TNF-α, COX-2, NF-κB                                         | [68]      |
|                                      |                                             | Mouse Eosinophils                             | 1 g/kg; 10 days|                                                                |                                                                           |           |
|                                      |                                             | PMACI-exposed HMC-1                           | 0.01, 0.1, 1 mg/mL; 1 h |                                                                |                                                                           |           |
| *Rosmarinic acid*                    |                                             | Mouse mast cells                              | 4 g/kg; 10 days| Amelioration of allergic inflammatory reactions                | ↓ IL-1β, IL-6, TNF-α, NF-κB                                               | [68]      |
|                                      |                                             | Mouse Eosinophils                             | 4 g/kg; 10 days|                                                                |                                                                           |           |
| *Spinacia oleracea* Linn. aqueous   | 25 µL/mL; 24 h                              | Viable cell number recovery                   |                |                                                                |                                                                           | [69]      |
| extract                              |                                             | Viable cell number recovery                   |                |                                                                |                                                                           |           |
| *Ze339*                              |                                             | Human nasal epithelial cells; inferior turbinates of patients | 3 µg/mg; 24 h  | Reduction of recruitment of inflammatory cells, inhibition of pro-inflammatory cytokine and chemokine response to viral mimics | ↑ G-CSF, ↓ IL-8, CCL-3, IL-6, STAT1, STAT3, STAT6                         | [70]      |

TDI, toluene diisocyanate; PMA, Phorbol myristate acetate; IL, Interleukin; H1R, H1-receptor; HDC, histidine decarboxylase; AR, allergic rhinitis; IgE, Immunoglobulin E; OVA, Ovalbumin; Cry j1, crystal proteins j1; CysLT1, Cysteinyl leukotrienes; IFN-γ, Interferon-gamma; DNP, Dinitrophenyl; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; PBMC, peripheral blood mononuclear cells; IkBa, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha; p-p38 MAPK, Phospho-p38 mitogen-activated protein kinases; COX, Cyclooxygenase; DNP-HSA, Dinitrophenyl-Human Serum Albumin; GM-CSF, Granulocyte-macrophage colony-stimulating factor; p-Syk, Phospho-Syk (Tyr525/526); p-Akt, Phospho-Akt (Ser473); p-ERK1/2, phospho-ERK1/2; STAT, Signal transducer and activator of transcription; G-CSF, Granulocyte-colony stimulating factor; CCL-3, Chemokine (c-C motif) ligand 3; ↑, up-regulation; ↓, down-regulation.

3.1.2. In Vivo Studies

There were 25 in vivo studies of plant-originated natural products (Table 2). Nurul et al. orally administered 200 mg of powdered *Albizia lebbeck* bark ethanol extract to toluene-2, 4-diisocyanate (TDI)-sensitized allergy rats once a day for 3 weeks [55]. IL-4, IL-5, and IL-13 were decreased. *Albizia lebbeck* reduced the amount of sneezing and nasal rubbing, thus alleviating nasal symptoms.

*Artemisia vulgaris* water extract was orally administered in a mugwort pollen-sensitized AR BALB/c mouse model for 15 days [71]. Except for the control group, each group was treated with 10, 50, and 100 µg/mL of the extract, respectively. *Artemisia vulgaris* water extract significantly declined the level of IgE. It also controlled the imbalance between T helper cell 1 (Th1) and T helper cell 2 (Th2) cytokines by increasing IL-12 and decreasing IL-4 and IL-5. The extract attenuated the symptoms of allergic rhinitis in a dose-dependent manner.

Awa-tea inhibited allergic diseases as well as stimulating anti-obesity and anti-oxidant activity [72]. TDI-sensitized rats were treated with 40 mg/kg of Awa-tea leaf hot-water extract once a day for 3 weeks. Decreased levels of IL-9 and IL-4 were observed.

Berberine, originated from *Berberis*, has been widely used in China as a gastrointestinal remedy and is known for its antibacterial, antifungal, and anti-inflammatory properties [73–76]. *Dermatophagoides farinae* (Derf)-induced AR BALB/c mice were orally administered 10 µg/mL of berberine for 5 days [77]. Serum IgE, GATA3 mRNA levels, and tissue eosinophil counts decreased, while Foxp3 increased compared with the control group. Berberine showed anti-inflammatory activity regarding allergic rhinitis through regulating the mechanism and function of diverse cells.

Shaha et al. orally administered 40 and 80 mg/kg of Brazilian green propolis (BGPP) to TDI-sensitized rats once a day for 22 days [56]. BGPP treatment led to the degradation of H1R mRNA, p-PKCδ, IL-9, IL-4, and IL-5.

*Bupleurum chinense* water extract (BCE), derived from *Bupleurum chinense*, is found in East Asia and is commonly used as a traditional herbal medicine [78]. BCE was orally administered (50, 100, and 200 mg/kg for 11 days) in an ovalbumin (OVA)-induced AR BALB/c mouse model [79]. It increased the expression of Th1/regulatory T cells (Treg)-related cytokines such as IL-10, IL-12, and Interferon-gamma (IFN-γ). On the other hand,
the secretion of Th2-related cytokines, IL-4, IL-5, and IL-13, including nasal lavage fluid eosinophil-specific chemoattractant Chemokine ligand 24 (CCL24) was suppressed.

Compound 40/80-induced systemic anaphylaxis mice and PCA mice were intraperitoneally administered with Chrysin (5, 7-dihydroxyflavone) at a dose range of 1–100 mg/kg 1 h before the challenge [58]. Chrysin blocked compound 40/80-induced fatal shock and reduced PCA reaction.

*Cinnamomum zeylanicum* bark hydroalcoholic extract has a long history of having been used as a traditional medicine to cure autoimmune diseases and cold in diverse regions such as India, China, Egypt, and Europe [80–82]. Aswar et al. induced AR in BALB/c mice by intranasal challenging OVA and injected 3, 10, and 30 µg/kg of *Cinnamomum zeylanicum* bark hydroalcoholic extract for 8 days [83]. The primary result was mast cell stabilization and subsequent prevention of IgE and histamine, which indicates that the extract effectively ameliorates nasal inflammation.

*Dryopteris crassirhizoma* (DC) is commonly used in Korea, Japan, and China to treat the common cold, tapeworm infection, and bacterial and inflammatory diseases [84]. OVA-induced AR BALB/c mice were treated with 100, 200, and 400 mg/kg of *Dryopteris crassirhizoma* ethanol extracts by oral gavage for 11 days [85]. DC increased the level of Treg cytokines in nasal fluid but decreased the activity of IgE, Immunoglobulin G1 (IgG1), and Immunoglobulin G2 (IgG2) cytokines in the blood. DC significantly prevented the occurrence of nasal allergic symptoms and the internal work of histamine.

TDI-sensitized rats were treated with 40 and 80 mg/kg of enzyme-treated (protease-degraded) royal jelly (3.5% (E)-10-hydroxy-2-decenolic acid and 0.6% 10-hydroxydecanoic acid) once a day for 22 days [56]. Decreased levels of H1R, p-PKCδ, IL-9, IL-4, and IL-5 were observed.

Epigallocatechin gallate, originated from *Camellia sinensis*, is a polyphenolic constituent of green tea catechins [86]. EGCG reduced the OVA-induced allergic rhinitis in female BALB/c mice at doses of 25, 50, and 100 mg/kg for 10 days. It inhibited the expression of IL-1β, IL-4, IL-6, and COX-2.

*DNP-HSA*-administered mouse bone marrow-derived mast cells (BMMCs) were treated with 0.2, 0.4, and 0.8 mg/mL of Gencydo® for 60 min [63]. After treatment, IL-8 and TNF-α levels were decreased.

Various kinds of literature have already found that soybean suppressed the development of chronic diseases, as it contains cancer risk-reducing properties [87,88]. *Glycine max* water extract, obtained from dried green soybean powder, was administered in the TDI-induced guinea pig rhinitis model at the concentrations of 30, 150, and 300 µg/kg for 28 days [89]. Green soybean extracts decreased levels of IgE serum, IL-4, B-cell activating factor (BAFF), and a proliferation-inducing ligand (APRIL) production. It effectively acted as an immune modulator of allergic rhinitis, preventing nasal mucosa secretions and allergic symptoms.

*Lindera obtusiloba* water extract was intraperitoneally administered to compound 48/80-induced systemic allergy mice at doses of 1, 10, and 100 mg/kg one hour before the challenge [64]. The anti-allergic effects of the extract were related to reduced TNF-α, IL-6, IkBα, and NF-κB.

Ortho-vanillic acid was orally administered to OVA-induced active systemic anaphylaxis (ASA) mice at doses of 2, 10, and 50 mg/kg for 14 days [65]. Furthermore, IgE-mediated passive cutaneous anaphylaxis (PCA) mice were orally treated with 50 mg/kg of saline-dissolved ortho-vanillic acid for 1 h. Kim et al. concluded that ortho-vanillic acid attenuated the OVA-induced active systemic anaphylaxis and lessened IgE-mediated cutaneous allergic reactions.

Efficacy of Osterici Radix (OR) root methanol extract was demonstrated by orally administering OVA-induced allergic rhinitis BALB/c mice with doses of 50 or 100 mg/kg from day 28 to day 34 [66]. OR extract attenuated disease progression, which is determined by nasal symptoms and histological changes of the nasal mucosa. Degradation of OVA-specific IgE and IL-4 and the elevation of IFN-γ were related to the effects.
Perilla frutescens var. acuta Kudo 30% ethanol extract powder (EPPF) inhibited mast cell-mediated immediate-type allergic reactions [68]. OVA-sensitized allergic rhinitis mice were orally treated with 0.01, 0.1, and 1 g/kg of EPPF before intranasal OVA challenge for 10 days. IL-1β, IL-6, TNF-α, COX-2, and NF-κB levels were reduced.

Piper nigrum L. ethanol extract (PNE), originated from Piperine, is widely used for treating bacteria-induced illnesses, tumors, diabetes, and inflammation [90–92]. OVA-induced AR BALB/c mice were orally administered with 50, 100, and 200 mg/kg PNE or 2.5 mg/kg Dexamethasone (Dex) for 13 days, respectively [93]. Piper nigrum L. ethanol extract positively inhibited nasal symptoms by suppressing the accumulation of inflammatory cells. The activation of inflammation-related cytokines signal transducer and activator of transcription 3 (STAT3) and nuclear factor kappa-light-chain-enhancer of activated B cells protein 65 (NFκBp65) were inhibited, and the action of anti-inflammatory cytokine Th1 was elevated. PNE showed significant differences compared with the naïve group and had a similar effect when compared with the Dex group.

Another study was conducted to determine the effect of Piper nigrum L. in treating allergic rhinitis. OVA-induced AR Swiss albino mice were treated with either 10, 20, or 40 mg/kg of Piper nigrum L. extract or 10 mg/kg of montelukast for 7 days [94]. The extract reduced the expression of IL-6, IL-1β, and IgE in contrast with the control group.

Propolis is a transformed form of plant resin produced by honey bees and has been used to treat burns and wounds, gastric ulcers, and prostate hyperplasia [95,96]. It is widely known for its diverse anti-microbial, anti-viral, and anti-inflammatory functions [97–100]. Yasar et al. orally applied 200 mg/kg of propolis to a group of Sprague Dawley (SD) rats, while the other groups were given mometasone furoate, ketotifen, and saline (sham treatment) [101]. Propolis, mometasone furoate, and ketotifen similarly down-regulated ciliary loss, inflammation, number of goblet cells, vascular proliferation, eosinophil count, and allergic symptoms scores. In the long-term, the observation results of symptom scores implied that propolis had a more powerful efficacy of inhibiting allergic reactions than sham medicines.

Rosae Multiflorae Fructus water extract (RMFE), originated from Rosae Multiflorae Fructus, is known for its anti-oxidative, analgesic, and anti-inflammatory properties [102]. Oral administration of 100, 200, and 400 mg/kg RMFE was implemented in an OVA-induced AR BALB/c mouse model for 13 days [103]. RMFE increased the Th1-associated cytokine IL-12 while inhibiting the action of Th2 related cytokines IL-4, IL-5, and IL-13 in nasal lavage fluid. Additionally, components of RMFE including hyperoside, isoquercitrin, and miquelianin were found to prevent IL-4 secretion.

OVA-sensitized allergic rhinitis mice were orally administered with 4 mg/kg of Rosmarinic acid for 10 days, which led to the degradation of IL-1β, IL-6, TNF-α IL-6, and NF-κB [68].

Spinacia oleracea Linn. aqueous extract, which is well-known for its vitamin content, improved the asthmatic symptoms induced by the OVA challenge and reduced the BAL’s eosinophil expression [69]. OVA-challenge asthmatic mice were orally treated with Spinacia oleracea Linn. extract at a dose of 25 μL/mL for 24 h.

Syzygium formosum (Wall.) Masam. leaves have been routinely used among indigenous Vietnamese people to treat various allergic symptoms, including dermatitis and rhinitis [104]. They also improved food allergy symptoms and inflammatory lesions in the gut. Syzygium formosum leaves extract was orally administered to chicken ovalbumin (cOVA)-induced food allergy mice at doses of 80 and 200 mg/kg for 13 days. T helper 2 cell cytokines (Th2 cytokines) (e.g., IL-4, IL-5, IL-10), and multiple c2 domains and transmembrane region proteins-1 (MCTP-1) were significantly decreased.

Xanthii Fructus, the ripe fruits of Xanthium sibiricum Patr., is a well-known herb used as traditional Chinese medicine [105]. OVA-sensitized Male BALB/C mice were orally treated with 1 g/kg of stir-fried Xanthii Fructus ethanol extract for 15 days. Phosphatidylcholine 40:8 (PC (40:8)) and L-valine were increased, thereby soothing nasal orifices and eliminating wind-dampness.
Wild grape (*Ampelopsis glandulosa*) has been reported to have anti-inflammatory, anti-hepatotoxic, and anti-osteoclastogenesis activity [72]. Islam et al. demonstrated that wild grape hot-water extract alleviated nasal symptoms and eosinophilic inflammation. The extract was orally treated to TDI-sensitized rats at doses of 25 and 50 mg/kg once a day, for 3 weeks. It inhibited the expression of p-PKCδ, H₁R, IL-9, IL-4, IL-5, and IL-33.

**Table 2.** In vivo studies—plant-originated natural products.

| Compound/Extract                                      | Source                          | Experimental Subject                        | Dose; Duration | Efficacy                                                                 | Mechanism                                                                 | Reference |
|-------------------------------------------------------|---------------------------------|--------------------------------------------|----------------|--------------------------------------------------------------------------|---------------------------------------------------------------------------|-----------|
| Albizia lebbeck bark ethanol extract                  | *Albizia lebbeck*               | TDI-sensitized allergy rats                | 200 mg; 3 weeks | Reduction of the amount of sneezing and nasal rubbing.                    | ↓ IL-4, IL-5, IL-13                                                      | [55]      |
| Artemisia vulgaris water extract                      | *Artemisia vulgaris*             | Mugwort pollen-injected AR BALB/c mice     | 10, 50, 100 µg/mL; 15 days | Reduction of allergic inflammation                                       | ↑ IL-12, ↓ IL-4, IL-5, IgE2, IgE                                      | [71]      |
| Awa-tea leaves hot water extract                      | *Setaria italica*                | TDI-sensitized rats                        | 40 mg/kg; 21 days | Inhibition of the allergic diseases                                       | ↓ IL-9, IL-4                                                            | [72]      |
| Berberine                                             | *Berberis*                       | Compound 48/80-induced systemic anaphylaxis mice | 1–100 mg/kg; 1 h | Blockage of compound 48/80-induced fatal shock                           | ↓ IgE, histamine                                                         | [58]      |
| Brazilian green propolis ethanol extract              | *Baccharis dracunculifolia*      | TDI-sensitized rats                        | 40, 80 mg/kg; 3 weeks | Improvement of allergic nasal symptoms                                  | ↓ H₁R, p-PKCδ, IL-9, IL-4, IL-5                                        | [56]      |
| Bupleurum chinense water extract                      | *Bupleurum chinense*             | OVA-induced AR BALB/c mice                 | 50, 100, 200 mg/kg; 11 days | Attenuation of allergic responses                                        | ↑ IL-10, IL-12, IFN-γ, ↓ IL-4, IL-5                                    | [79]      |
| Chrysin (5,7-dihydroxyflavone)                        | *Passiflora caerulea*            | Compound 48/80-induced systemic allergy mice | 1–100 mg/kg; 1 h | Suppression of nasal inflammation                                        | ↓ IgE, histamine                                                         | [63]      |
| Cinnamomum zeylanicum bark hydroalcoholic extract     | *Cinnamomum zeylanicum*          | OVA-induced AR BALB/c mice                 | 3, 10, 30 µg/kg; 8 days | Attenuation of nasal inflammation                                        | ↓ IgE, histamine                                                         | [85]      |
| Dryopteris crassirhiza ethanol extract                 | *Dryopteris crassirhiza*         | OVA-induced AR BALB/c mice                 | 100, 200, 400 mg/kg; 11 days | Amelioration of nasal inflammation                                       | ↓ IgE, IgG1, IgG2                                                        | [85]      |
| Enzyme-treated (protease-degraded) Royal Jelly        | *Apis cerana*                    | TDI-sensitized rats                        | 40, 80 mg/kg; 3 weeks | Improvement of allergic nasal symptoms                                  | ↓ H₁R, p-PKCδ, IL-9, IL-4, IL-5                                        | [56]      |
| Epigallocatechin gallate                              | *Camellia sinensis*              | OVA-induced mice                           | 25, 50, 100 mg/kg; 10 days | Reduction of allergic rhinitis                                            | ↓ IL-1β, IL-4, IL-6, COX-2                                            | [86]      |
| Glycine max water extract                             | *Glycine max*                    | (2,4-TDI)-induced rhinitis guinea pigs     | 30, 150, 300 µg/kg; 28 days | Suppression of nasal inflammation Decrease of allergic responses         | ↓ IgE                                                                     | [89]      |
| Lindera obtusiloba water extract                      | *Lindera obtusiloba*             | Compound 48/80-induced systemic allergy mice | 1, 10, 100 mg/kg; 1 h | Reduction of histamine release Inhibition of systemic and local allergic reaction | ↑ 1α,8α, ↓ TNF-α, IL-6, NF-κB                                          | [64]      |
| Ortho-vanillic acid                                   | *Amomum xanthioides*             | OVA-induced ASA mice                       | 2, 10, 50 mg/kg; 14 days | Attenuation of the ovalbumin-induced ASA                                  | ↓ TNF-α, IL-4, p-Lyn, p-Syk, p-Akt                                      | [65]      |
Table 2. Cont.

| Compound/Extract                  | Source                          | Experimental Subject                     | Dose; Duration | Efficacy                                                                 | Mechanism                                                                                     | Reference |
|-----------------------------------|---------------------------------|------------------------------------------|----------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-----------|
| Ostericum koreanum root methanol extract | Ostericum koreanum              | OVA-induced allergic rhinitis BALB/c mice | 50, 100 mg/kg; 7 days | Attenuation of disease progression as determined by nasal symptoms and histological changes of the nasal mucosa | ↑ IFN-γ ↓ OVA-specific IgE, IL-4                                                               | [66]      |
| Perilla frutescens var. acuta Kudo 30% ethanol extract powder | Perilla frutescens var.         | OVA-sensitized allergic rhinitis mice    | 0.01, 0.1, 1 g/kg; 10 days | Amelioration of allergic inflammatory reactions                           | ↓ IL-1β, IL-6, TNF-α, COX-2, NF-κB                                                            | [68]      |
| Piper nigrum L. ethanol extract    | Piper nigrum L.                 | OVA-induced AR BALB/c mice              | 50, 100, 200 mg/kg; 13 days | Inhibition of allergic nasal symptoms Suppression of nasal inflammation   | ↓ STAT3, NFκB                                                                                 | [93]      |
| Piper nigrum L. extract            | Piper nigrum L.                 | OVA-induced AR Swiss albino mice        | 10, 20, 40 mg/kg; 7 days | Exhibits immunomodulatory and anti-inflammatory activity                 | ↓ IL-6, IL-1β, IgE                                                                            | [94]      |
| Propolis                           | SD rats                         |                                          | 200 mg/kg; 21 days | Inhibition of allergic symptoms                                           |                                                                                               | [101]     |
| Rosae Multiflorae Fructus water extract | Rosae Multiflorae Fructus       | OVA-induced AR BALB/c mice              | 100, 200, 400 mg/kg; 13 days | Inhibition of allergic symptoms Immunomodulatory effect on allergic rhinitis | ↑ IL-12 ↓ IL-4, IL-5, IL-13                                                                   | [103]     |
| Rosmarinic acid                    |                                 |                                          | 4 mg/kg; 10 days | Amelioration of allergic inflammatory reactions                           | ↓ IL-1β, IL-6, TNF-α, NF-κB                                                                   | [68]      |
| Spinacia oleracea Linn. aqueous extract | Spinacia oleracea Linn.        | OVA-challenge asthmatic mice            | 25 µL/mL, 24 h | Improvement of the asthmatic symptoms induced by OVA-challenge Reduction of the BAL’s eosinophil expression | ↓ IL-4, IL-13, IgE                                                                            | [69]      |
| Syzygium formosum leaves extract   | Syzygium formosum (Wall.) Masam. | cOVA-induced food allergy mice          | 80, 200 mg/kg; 13 days | Improvement of the food allergy symptoms and the inflammatory lesion in the gut. | ↓ Th2 cytokines (e.g., IL-4, IL-5, IL-10), MCTP-1                                            | [104]     |
| Xanthii Fructus ethanol extract    | Xanthium sibiricum Patr.       | OVA-sensitized Male BALB/C mice         | 1 g/kg; 15 days | Alleviation of nasal orifices and elimination of wind-dampness            | ↑ PC(40:8), L-valine                                                                          | [105]     |
| Wild grape hot water extract       | Ampelopsis glandulosa           | TDI-sensitized rats                     | 25, 50 mg/kg; 21 days | Alleviation of the nasal symptoms Alleviation of the eosinophilic inflammation | ↓ aPKCα, HIR, IL-9, IL-5, IL-33                                                                | [72]      |

TDI, toluene diisocyanate; IL, Interleukin; H1R, H1-receptor; AR, allergic rhinitis; IgE, Immunoglobulin E; Derf, Dermatophagoides farinae; OVA, Ovalbumin; Foxp3, forkhead box P3; IFN-γ, Interferon-gamma; CCL24, Chemokine ligand 24; PCA, Passive cutaneous anaphylaxis; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; IgG1, Immunoglobulin G1; IgG2, Immunoglobulin G2; IκBα, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha; COX, Cyclooxygenase; ASA, active systemic anaphylaxis; p-Syk, Phospho-Syk (Tyr525/526); p-Akt, Phospho-Akt (Ser473); STAT, signal transducer and activator of transcription; NFκBp65, nuclear factor kappa-light-chain-enhancer of activated B cells protein 65; PC(40:8), phosphatidylcholine 40:8; TH2, T helper 2 cell; MCTP-1, multiple c2 domains and transmembrane region proteins-1; ↑, up-regulation; ↓, down-regulation.

3.2. Fungi and Minerals-Originated Natural Products

Although plant-derived natural products are the most abundant materials for AR treatments, several studies cover compounds derived from fungi and minerals.

3.2.1. In Vitro Studies

There were two in vitro studies of fungi and minerals (Table 3). Amber has been used to improve muscle pain, headaches, skin allergy, etc. [106]. RBL-2H3 cells were treated...
with 2 μL of 25 μg/mL Kuji amber methanol extract for 30 min. The extract induced the degradation of phospho-ERK1/2 (p-ERK1/2) and LTC4, thus inhibiting nasal blockage degranulation of RBL-2H3 cells. Meanwhile, kujigamberol (15,20-dinor-5,7,9-labdatrien-18-ol), isolated from Kuji amber, was also treated to RBL-2H3 cells in the same way as the Kuji amber methanol extract.

Table 3. In vitro studies—fungi and minerals-originated natural products.

| Classification | Compound                      | Source      | Cell Line/Animal Model | Dose/Duration | Efficacy                           | Mechanism                           | Reference |
|----------------|--------------------------------|-------------|------------------------|---------------|------------------------------------|-------------------------------------|-----------|
| Mineral        | Kuji amber methanol extract   | Succinum    | RBL-2H3                | 2 μL (0–25 μg/mL); 30 min | Inhibition of the degradation of RBL-2H3 cells | ↓ p-ERK1/2, LTC4                     | [106]     |
| Mineral        | Kujigamberol (15,20-dinor-5,7,9-labdatrien-18-ol) | Succinum    | RBL-2H3                | 2 μL (0–25 μg/mL); 30 min | Inhibition of the degradation of RBL-2H3 cells | ↓ p-ERK1/2, LTC4                     | [106]     |

p-ERK1/2, phospho-extracellular signal-regulated kinase1/2; LTC4, Leukotriene C4; ↓, down-regulation.

3.2.2. In Vivo Studies

There were three in vivo studies of fungi and minerals (Table 4). *Ganoderma lucidum* has long been used in East Asia as a remedy for cancer, hypertension, hepatitis, hyperglycemia, and bronchitis [107–109]. Cedar pollen extract-sensitized AR guinea pig models were orally administered with *Ganoderma lucidum* powder suspended in water at the doses of 100 and 1000 mg/5 mL/kg for 8 weeks [110]. Treatment of *Ganoderma lucidum* effectively inhibited nasal inflammatory symptoms via suppressing CysLT1 receptor activation.

Table 4. In vivo studies—Fungi and minerals.

| Classification | Compound                          | Source                  | Cell Line/Animal Model | Dose/Duration | Efficacy                           | Mechanism                           | Reference |
|----------------|-----------------------------------|-------------------------|------------------------|---------------|------------------------------------|-------------------------------------|-----------|
| Fungi          | *Ganoderma lucidum* powder        | *Ganoderma lucidum*     | Cedar pollen extracts-sensitized AR guinea pigs | 100, 1000 mg/5 mL/kg; 8 weeks | Inhibition of nasal inflammation | ↓ CysLT1                             | [110]     |
| Mineral        | Kuji amber methanol extract       | Succinum                | OVA-induced rhinitis guinea pigs | 20 μg; 10 min, 1 h | Inhibition of nasal blockade       | ↓ p-ERK1/2, LTC4                     | [106]     |
| Mineral        | Kujigamberol (15,20-dinor-5,7,9-labdatrien-18-ol) | Succinum                | OVA-induced rhinitis guinea pigs | 20 μg; 10 min, 1 h | Inhibition of nasal blockade       | ↓ p-ERK1/2, LTC4                     | [106]     |

CysLT1, Cysteinyl leukotriene receptor 1; OVA, ovalbumin; p-ERK1/2, phospho-extracellular signal-regulated kinase1/2; LTC4, Leukotriene C4; ↓, down-regulation.

OVA-induced rhinitis guinea pigs were intranasally administered 20 μg of Kuji amber methanol extract for 10 min, 1 h after OVA exposure [106]. Additionally, Kujigamberol (15,20-dinor-5,7,9-labdatrien-18-ol) was orally administered to OVA-induced rhinitis guinea pigs. Both experiments resulted in the degradation of p-ERK1/2 and LTC4.

3.3. Decoctions of Natural Products

A decoction is an extract obtained by boiling one or more herbal materials for medical purposes. Various studies reported that decoctions have anti-AR effects in several experimental models.

3.3.1. In Vitro Studies

There were four in vitro studies of decoctions (Table 5). Gami-hyunggyeeyeongytang is a traditional decoction used for treating allergic disorders [111]. Human mast cell line (HMC-1) cells were treated with Gami-hyunggyeeyeongytang at doses of 1, 10, or 100 μg/mL for an hour. Gami-hyunggyeeyeongytang alleviated the nasal symptoms of AR, such as sneezing, by suppressing IgE, IL-5, IL-6, IL-1β, monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-2, and caspase-1.
### Table 5. In vitro studies—decoctions of natural products.

| Name | Constitutions | Experimental Subject | Dose; Duration | Efficacy | Mechanism | Reference |
|------|---------------|-----------------------|----------------|----------|-----------|-----------|
| Gami-hyunggyeyeongyotang | Schizonepetae Spica (Nepeta tenuifolia Benth.), Forsythiae Fructus (Forsythia viridissima Lindl.), Saposhnikoviae Radix (Saposhnikovia divaricata (Turcz.) Schischk.), Angelicae Radix (Angelica acutiloba Kitagawa), Cnidii Rhizoma (Cnidium officinale Makino), Paonieae Radix Alba (Paonia lactiflora Pallas), Angelicae Dahuricae Radix (Angelica dahurica Bentham et Hooker), Bupleuri Radix (Bupleurum falcatum Linne), Scutellariae Radix (Scutellaria baicalensis Georgi), Angelicae Radix (Angelica acutiloba Kitagawa), Cnidii Rhizoma (Cnidium officinale Makino), Paeoniae Radix Alba (Paeonia lactiflora Pallas), Angelicae Dahuricae Radix | HMC-1 | 1, 10, 100 µg/mL; 1 h | Alleviation of the symptoms of AR | ↓ IgE, IL-5, IL-6, IL-1β, MCP-1, MIP-2, caspase-1 | [111] |
| Mahuang Fuzi Xixin Decoction | Ephedrae Herba (Ephedra sinica Stapf, Ephedra intermedia Schrenk & C.A. Mey, or Ephedra equisetina Bunge), Aconiti Lateralis Radix (Aconitum carmichaelii Debeaux), Asiasari Radix (Asarum heterotropoides f. mandshuricum (Maxim.) Kitag.) | IgE-activated RBL-2H3 | M136: 3, 10, 30 µM; 1 h | Anti-inflammatory effect | ↓ PGE2 | [112] |
| Senn-kinn-naidaku-sann | Ginseng Radix, Angelicae Radix, Astragali Radix, Cnidii Rhizoma, Sinomeni Caulis et Rhizoma, Platycodonis Radix, Magnoliae Cortex, Angelicae Dahuricae Radix, Glycyrrhizae Radix | RAW264.7 | 0.01, 0.1, 1, 10 µg/mL; 24 h | Inhibition of inflammatory response | ↑ TLR4, IL-12 | [113] |
| Shenqi | Angelicae Dahuricae Radix (Angelica dahurica (Hoffm.) Benth. & Hook f. ex Franch. & Sav.), Scutellariae Radix (Scutellaria baicalensis Georgi), Lonicerae Japonicae Flos (Lonicera japonica Thunb.), Menthae Haplocalycis Herba (Mentha canadensis L.), Angelicae Radix (Angelicae acutiloba Kitagawa), Codonopsis Radix (Codonopsis pilosula subsp. tangshen (Oliv.) D.Y.Hong), Isatisis Folium (Isatis tinctoria L.), Taraxaci Herba (Taraxacum mongolicum Hand. -Mazz.), Agrimoniae Herba (Agrimonia pilosa Lede), Asiasari Radix et Rhizome (Asarum sieboldii Miq.) | RBL-2H | 50, 100, 200 µg/mL; 1 h | Alleviation of symptoms of AR | ↓ β-Hex, histamine | [114] |

AR, allergic rhinitis; β-Hex, β-hexosaminidase; IL-5, interleukin 5; IgE, immunoglobulin E; HMC-1, human mast cell line; IL-6, interleukin 6; IL-1β, interleukin 1 beta; MCP-1, monocyte chemoattractant protein; MIP-2, macrophage inflammatory protein; STAT6, signal transducer and activator of transcription 6; RBL-2H3, rat basophilic leukemia; PGE2, prostaglandin E2; TLR4, Toll-like receptor 4; IL-12, interleukin 12; ↑, up-regulation; ↓, down-regulation.
Mahuang Fuzi Xixin had an anti-inflammatory effect by decreasing PGE$_2$ [112]. IgE-activated rat basophilic leukemia (RBL-2H3) cells were treated with M136 at doses of 3, 10, or 30 µM, M188 at doses of 5 or 10 µM, M234 at doses of 2 or 5 µM, and M289 at doses of 3, 10, or 30 µM for 1 h.

The expression of Toll-like receptor 4 (TLR4) and production of IL-12 increased when RAW264.7 was pre-stimulated by Senn-kinn-naidaku-sann, thus inhibiting the inflammatory effects [113]. RAW264.7 was treated at doses of 0.01, 0.1, 1, and 10 µg/mL for 24 h.

Shenqi affected RBL-2H3 cells, decreasing β-hexosaminidase and histamine when treated at doses of 50, 100, and 200 µg/mL for 1 h [114].

3.3.2. In Vivo Studies

There were seventeen in vivo studies of decoctions (Table 6). Biyeom-Tang has been used to treat allergic rhinitis (AR) traditionally [115]. The ethanol extract of Biyeom-Tang inhibited allergic and inflammatory responses. The decoction suppressed β-hexosaminidase (β-Hex) when treated to BMMC from BALB/c mice at doses of 12.5, 25, or 50 µg/mL for an hour. Ethanol extract of Biyeom-Tang also suppressed the production of prostaglandin D$_2$ (PGD$_2$) and LTC$_4$ on BMMC in BALB/c mice when the mice were treated with 6.3, 12.5, or 25 µg/mL of the extract for one hour. Additionally, the extract was orally administered with doses of 50, 100, or 200 mg/kg to OVA-induced AR BALB/c mice for 7 days. It was found that levels of IL-4, IL-5, IL-10, and IL-13 decreased.

Biyuanling Granules were orally administered to TDI-induced AR guinea pigs at doses of 4, 8, or 16 mg/g for 7 days once a day [116]. The decoction inhibited the inflammatory response by increasing Bcl-2 Associated X Protein (Bax) expression and suppressing IL-4, human SARS-specific immunoglobulin (SIgE), tumor necrosis factor α (TNF-α), pulmonary surfactant associated protein (SP), vascular cell adhesion molecule-1 (VCAM-1), and transcription factor p65 (p65).

Bu-Zhong-Yi-Qi-Tang improved the AR-like symptoms by increasing interferon-gamma (IFN-γ), Foxp3 and decreasing IgE, IL-4, and cluster of differentiation 4 (CD4) in OVA- and alum-induced AR BALB/c mice [117]. Group I mice were gavage-fed 10 g/100 mL of Bu-Zhong-Yi-Qi-Tang for 10 days, and Group II for 19 days.

OVA-induced AR BALB/c mice were orally administered 134 mg/kg of Gami-hyunggayeongyotang for 11 days [111]. IgE, IL-5, IL-6, IL-1β, MCP-1, MIP-2, and caspase-1 decreased, improving the symptoms of AR.

Hyeonggaeyeongyo-Tang is a traditional treatment for otolaryngology symptoms [118]. The decoction suppressed the progression of AR by decreasing IL-4, IL-13, and leukemia inhibitory factor (LIF). OVA-induced AR BALB/c mice were orally administered Hyeonggaeyeongyo-Tang at doses of 101, 202, or 404 mg/kg for 14 days.

KOB03 has been commonly used to treat hyperhidrosis, allergic asthma, and allergic rhinitis [119–121]. OVA-induced AR BALB/c mice and SD rats were orally administered 100 or 200 mg/kg of KOB03 for 7 days. The secretion of cytokines TNF-α, IL-1β, IL-6, and IL-8 were reduced [122]. These results confirmed that the decoction prohibits IgE production and Th2 cytokines, thus regulating symptoms of allergic inflammations.

In another study, 500 mg/kg of KOB03 was orally injected into OVA-induced AR BALB/c mice for 8 consecutive days [123]. KOB03 controlled the levels of IgE, LTC$_4$, IL-4, and IL-1β, thus significantly increasing Th1 cytokine and down-regulating Th2 cytokine. KOB03 showed its efficacy in inhibiting nasal inflammation by controlling diverse allergic mediators and Th1/Th2 balance.

Mahuang Fuzi Xixin decoction alleviated the symptoms of AR in OVA-induced AR specific pathogen-free (SPF) Wistar rats when orally administered in quantities of 1.52 g/mL daily for 10 days [124]. Mahuang Fuzi Xixin decoction reduced IgE, histamine, IFN-γ, IL-4, GATA3, and STAT6.

OVA-induced AR BALB/c mice were orally administered 1 mg/mL of Pyeongwee-San for 10 days [125]. The decoction increased IFN-γ and decreased IgE, IL-4, TNF-α, IL-1β, MIP-2, intercellular adhesion molecule 1 (ICAM-1), and COX-2.
The effect of Qi-fang-bi-min-tang combined with mesenchymal stem cells (MSCs) on AR treatment was investigated [126]. OVA-induced AR SD rats were injected with $5 \times 10^6$ MSCs and 2% of qi-fang-bi-min-tang for 19 days, resulting in the inhibition of AR symptoms by suppressing IFN-\(\gamma\), IL-17, IL-4, TNF-\(\alpha\), and IgE. The equal amount of MSCs and Qi-fang-bi-min-fang showed a similar effect when tested in OVA-induced AR BALB/C mice. Additionally, TNF-\(\alpha\), IL-6, IFN-\(\gamma\), IL-4, and IL-17 were suppressed by 20% of Qi-fang-bi-min-tang.

Senn-kinn-naidaku-sann alleviated the symptoms of AR in OVA-induced AR C3H/HeN mice by increasing IFN-\(\gamma\) and decreasing IgE, immunoglobulin G1 (IgG1), IL-4, and IL-5 [113]. The mice were orally administered with 100 and 1000 mg/kg of the decoction for 7 days. The same dose had no enhancement of AR in OVA-induced AR C3H/HeJ mice.

OVA-sensitized primary spleen lymphocytes of Wistar rats were treated with 50, 100, and 200 \(\mu\)g/mL of Shenqi for 7 days [114]. Increased T-bet and decreased GATA3, p-STAT6, and suppressor of cytokine signaling 1 (SOCS1) were observed. Meanwhile, Shenqi on OVA-induced AR Wistar rats at doses of 0.9, 2.7, and 8.1 g/kg for 7 days increased IFN-\(\gamma\), T-bet, and suppressed IL-4, IgE, GATA3, phospho-STAT6 (p-STAT6), and SOCS1.

OVA-induced AR BALB/c mice were fed with 20 mg/mL of So-Cheong-Ryong-Tang for 14 days [127]. So-Cheong-Ryong-Tang suppressed the progression of AR by decreasing IL-4, IL-6, IL-1\(\beta\), TNF-\(\alpha\), and LIF. In another study, OVA-and-alum-induced AR BALB/c mice were orally administered with 1 g/kg of So-Cheong-Ryong-Tang per day for 7 days [128]. So-Cheong-Ryong-Tang alleviated the symptoms of AR such as nasal rubbing and sneezing by increasing levels of IgG2a and IFN-\(\gamma\) while decreasing levels of IgE, IL-4, IgG1, and IL-5.

Tong Qiao is new Chinese medicine developed by Chengdu Huashen Zhiyao, Ltd. Co., [129]. OVA-induced AR SD rats were given intranasal drops of Tong Qiao, 10 \(\mu\)L/kg per nostril per treatment, three times a day, for 7 or 15 days. Tong Qiao alleviated the symptoms of AR by suppressing eotaxin, IL-5, and IL-13.

Xingbi gel is a traditional application prescribed for the cure of allergic rhinitis [130]. OVA-induced AR guinea pig models were sensitized with 50 \(\mu\)L/kg of Xingbi gel for 12 days. Xingbi gel regulated the secretion of Leukotriene E4 (LTE\(_4\)) and IgE, which led to the decreased production of inflammatory mediators and cytokines.

Yiqi Wenyang Fang is known to treat AR patients with a cold deficiency in the lung and spleen [131]. Yiqi Wenyang Fang inhibited inflammatory response and alleviated the symptoms of AR in OVA-induced AR SD rats by decreasing IL-10, transforming growth factor-beta 1 (TGF-\(\beta1\)), IL-4, and IL-13. The rats were given 1.6 g/mL of Yiqi Wenyang Fang per day, by gavage, for 28 days.

### 3.4. Clinical Trials

Several clinical trials with natural products from plants and animals were conducted (Table 7). Depigoid 50% Grasses/50% Olea europaea or Depigoid 50% Grasses/50% Parietaria judaica were administered to patients with allergic rhinitis or rhinoconjunctivitis with or without seasonal asthma [132]. This trial was a phase II, prospective, open uncontrolled, and non-randomized study. The study evaluated the safety and tolerance of a rush build-up of administration of Depigoid forte pollen with the first maintenance dose administered 4 weeks later.
Table 6. In vivo studies—decoctions of natural products.

| Name                        | Constitutions                                                                 | Experimental Subject                                      | Dose; Duration | Efficacy                                                                 | Mechanism                                                                 | Reference |
|-----------------------------|-------------------------------------------------------------------------------|-----------------------------------------------------------|----------------|--------------------------------------------------------------------------|----------------------------------------------------------------------------|-----------|
| Biyeom-Tang (ethanol extract) | Xanthii Fructus (Xanthium strumarium L.), Trichosanthis Sement (Trichosanthes kirilowii Maxim.), Angelicae Dahuricae Radix, Menthae Herba (Mentha arvensis L.) | BMMCs from BALB/c mice                                   | 12.5, 25, 50 µg/mL; 1 h | Inhibition of allergic and inflammatory effects                           | ↓ β-Hex                                                                                  | [115]    |
|                             |                                                                                | BMMCs from BALB/c mice                                   | 6.3, 12.5, 25 µg/mL; 1 h |                                                                          | ↓ PGD₂, LTC₄                                                                |           |
|                             |                                                                                | OVA-induced AR BALB/c mice                               | 50, 100, 200 mg/kg; 7 days |                                                                          | ↓ IL-4, IL-5, IL-10, IL-13                                                   |           |
| Biyuanling                   | Xanthium strumarium subsp. sibiricum (Patrin ex Widder) Greuter, Lonicera japonica Thunb., Glycyrrhiza uralensis Fisch., Scutellaria baicalensis Georgi | TDI-induced AR Guinea pigs                               | 4, 8, 16 mg/g; 7 days | Inhibition of inflammatory response                                       | ↑ Bax                                                                                   | [116]    |
|                             |                                                                                |                                                           |                |                                                                          | ↓ IL-4, SlgE, TNF-α, SP, VCAM-1, P65                                      |           |
| Bu-Zhong-Yi-Qi-Tang          | Astragali Radix, Ginseng Radix, Atractylodes macrocephala Koelz., Glycyrrhiza Radix, Cimicifugae Rhiza, Bupleuri Radix, Aurantii Nobileis Pericarpium Citri Unshiius Pericarpium, finger citron, Chinese magnolia vine fruit | (OVA-and-alum)-induced AR BALB/c mice                    | 10 g/100 mL.; 10, 19 days | Improvement of the AR-like symptoms                                       | ↑ IFN-γ, Foxp3                                      | [117]    |
|                             |                                                                                |                                                           |                |                                                                          | ↓ IgE, IL-4, CD4                                                            |           |
| Gami-huynggreyeyongyotang   | Schizonepetae Spica ( Nepeta tenuifolia Benth.), Forsythiae Fructus ( Forsythia viridisima Lindl.), Saposhnikoviae Radix ( Saposhnikovia divaricata (Turcz.) Schisch.) , Angelicae Radix ( Angelica acutiloba Kitagawa), Cnidii Rhzoma ( Cnidium officinale Makino), Paoniae Radix Alba ( Paonia lactiflora Pallas), Angelicae Dahuricae Radix ( Angelica dahurica Bentham et Hooker), Bupleuri Radix ( Bupleurum falcatum Linne), Scutellariae Radix ( Scutellaria baicalensis Georgi), Auranti Fructus Immaturus ( Citrus aurantium Linn.), Gardeniae Frutus ( Gardenia jasminoides Ellis), Platycodi Radix ( Platycodon grandiflorum A. de candolle), Glycyrrhizae Radix ( Glycyrrhiza uralensis Fischer), Ulmi Cortex ( Ulmus macrocarpa Hance), Xanthi Fructus ( Xanthium strumarium Linn.), Magnoliae Flos ( Magnolia kobus De Candolle), Rubiae Radix ( Rubia alea Nakai) | OVA-induced AR BALB/c mice                                                 | 134 mg/kg; 11 days | Alleviation of the symptoms of AR                                         | ↓ IgE, IL-5, IL-6, IL-1β, MCP-1, MIP-2, caspase-1 | [111]    |
| Hyeonggayeeyongyo-Tang       | Schizonepetpa Spica, Forsythyiae Fructus, Saposhnikoviae Radix, Angelicae Gigantis Radix, Cnidii Rhzoma, Paoniae Radix Alba, Bupleuri Radix, Aurantii Fructus, Scutellariae Radix, Gardeniae Fructus, Angelicae Dahuricae Radix, Platycodi Radix, Glycyrrhizae Radix | OVA-induced AR BALB/c mice                               | 101, 202, 404 mg/kg; 14 days | Suppression of the progression of AR                                       | ↓ IL-4, IL-13, LIF                                                              | [118]    |
| KOB03                        | Atractylodis Rhzoma Alba ( Atractylodes japonica Koiz.), Astragalus Radix ( Astragalus membranaceus Bunge), Saposhnikoviae Radix ( Saposhnikovia divaricata Schischkin), Osterici Radix ( Ostericum koreanum maximowicz), Scutellariae Radix ( Scutellaria baicalensis Georgi) | OVA-induced AR BALB/c mice                               | 100, 200 mg/kg; 7 days | Regulation of allergic inflammation                                        | ↓ TNF-α, IL-1β, IL-6, IL-8                                                       | [122]    |
### Table 6. Cont.

| Name | Constitutions | Experimental Subject | Dose; Duration | Efficacy | Mechanism | Reference |
|------|---------------|----------------------|----------------|----------|-----------|-----------|
| KOB03 | Atractylodis Rhizoma White (Atractylodes japonica Koiz.), Astragalus Root (Astragalus membranaceus Bunge), Saposhnikovia Root (Saposhnikovia divaricata Schischkin), Ostericum Root (Ostericum koreanum maximovicz), Scutellaria Root (Scutellaria baicalensis Georgi) | OVA-induced AR BALB/c mouse model | 500 mg/kg; 8 days | Inhibition of nasal inflammation | ↓ IgE, LTC4, IL-4, and IL-1β | [123] |
| Mahuang Fuzi Xixin Decoction | Ephedrae, Aconiti Lateralis Radix, Asarum | OVA-induced AR SPF Wistar rats | 1.52 g/mL; 10 days | Alleviation of the symptoms of AR | ↓ IgE, histamine, IFN-γ, IL-4, GATA3, STAT6 | [124] |
| Pyeongwee-San extract (KMP6) | Atractylodes japonica Koizd. ex Kitam., Machilus thunbergii Siebold & Zucc., Citrus reticulata Blanco, Zizyphus jujube, Glycyrrhiza uralensis Fisch., Zingiber officinale Roscoe | OVA-induced AR BALB/c mice | 1 mg/mL; 10 days | Amelioration of AR | ↓ IFN-γ, IL-17, IL-4, TNF-α, IL-6, IFN-γ, IL-4, IL-17 | [125] |
| Qt-fang-bi-min-tang (QFBMT) | Astragali Radix, Ramulus Cinnamomi, Saposhnikoviae Radix, Magnoliae Flos, Atractylodes Macrocephalae Rhizoma, Zingiberis Rhizoma Alba, Glycyrrhizae Radix | OVA-induced AR SD rats | 5 × 10^6 MSCs; 2% QFBMT; 19 days | Inhibition of AR symptoms combined with MSCs | ↓ IFN-γ, IL-17, IL-4, TNF-α, IgE | [126] |
| Senn-kimm-naidaku-sann | Ginseng Radix, Angelicae Radix, Astragali Radix, Cnidii Rhizoma, Sinomenii Caulis et Rhizoma, Platy codemis Radix, Magnoliae Cortex, Angelicae Dahuricae Radix, Glycyrrhizae Radix | OVA-induced AR C3H/HeN mice | 100, 1000 mg/kg; 7 days | Alleviation of the symptoms of AR | ↑ IFN-γ | [114] |
| Shenqi | Angelicae Dahuriae Radix (Angelica dahurica (Hoffm.) Benth. & Hook.f. ex Franch. & Sav.), Scutellariae Radix (Scutellaria baicalensis Georgi), Lonicerae Japonicae Flos (Lonicera japonica Thunb.), Menthae Haplocalycis Herba (Menta canadensis L.), Astragali Radix (Astragalus propinqua Schischkin), Codonopapis Radix (Codonopsis pilosula subsp. tangshen (Oliv.) D.Y.Hong), Isatidis Folium (Isatis tinctoria L.), Taraxaci Herba (Taraxacum mongolicum Hand.-Mazz.), Agrimoniae Herba (Agrimonia pilose Lede.), Asiasari Radix et Rhizome (Asarum sieboldii Miq.) | OVA-sensitized primary spleen lymphocytes of Wistar rats | 50, 100, 200 µg/mL; 7 days | Alleviation of symptoms of AR | ↑ T-bet | [113] |
| So-Cheong-Ryong-Tang | Asarum sieboldii Miq., Glycyrrhiza uralensis Fisch., Ephedra sinica Stapf, Cinnamomum cassia Blume, Peony root, Pinellia ternata (Thunb.) Makino, Schisandra chinensis (Turcz.) Baill., Zingiber officinale Roscoe | OVA-induced AR BALB/c mice | 20 mg/mL; 14 days | Suppression of the progression of AR | ↓ IL-4, IL-6, IL-1β, TNF-α, LIF | [127] |
Table 6. Cont.

| Name                          | Constitutions                                                                 | Experimental Subject       | Dose; Duration | Efficacy                          | Mechanism                        | Reference |
|-------------------------------|------------------------------------------------------------------------------|----------------------------|----------------|-----------------------------------|-----------------------------------|-----------|
| So-Choong-Ryong-Tang          | Pinelliae Tuber (*Pinellia ternata* (Thunb.) Makino), Ephedrae Herba *(Ephedra sinica* Stapf), Schisandrae Fructus *(Schisandra chinensis* (Turcz.) Baill.), *Paoniae Radix* (*Paonia lactiflora* Pall.), Glycyrrhizae Radix (*Glycyrrhiza uralensis* Fisch.), Zingiberis Siccatum Rhizoma *(Zingiber officinale* Roscoe), *Asiasari Radix* *(Asarum sieboldii* Miq.), *Cinnamomi Cortex* *(Cinnamomum cassia* (L.) J.Presl) | (OVA-and-alum)-induced AR BALB/c mice | 1 g/kg; 7 days | Alleviation of the symptoms of AR | ↑ IgG2a, IFN-γ ↓ IgE, IL-4, IgG1, IL-5 | [128]     |
| Tong Qiao                     | Angelicae Dahuricae Radix, *Gleditsia sinensis* Lam., Magnoliaceae Flos     | OVA-induced AR SD rats     | 10 µL/kg; 7, 15 days | Alleviation of the symptoms of AR | ↓ eotaxin, IL-5, IL-13            | [129]     |
| Xingbi gel                    | Cynanchi Paniculati Radix *(Cynanchum paniculatum* (Bunge) Kitag. *ex* H.Hara), Cicadidae Periostracum (cicada slough), Bovis Calculus (bezoar), Borneolum Syntheticum (borneol) | OVA-induced AR guinea pigs | 50 µL/kg; 12 days | Alleviation of the symptoms of AR | ↓ LTE₄, IgE                          | [130]     |
| Yiqi Wenyang Fang             | Astragalus membranaceus (Fisch.) Bunge, *Codonopsis pilosa* (Franch.) Nannf., Zingiberis Rhizoma, Cinnamomii Ramulus, *Ephedra sinica* Stapf, *Schisandra chinensis* (Turcz.) Baill. | OVA-induced AR SD rats     | 1.6 g/mL; 28 days | Inhibition of inflammatory response | Alleviation of the symptoms of AR | ↓ IL-10, TGF-β1, IL-4, IL-13 | [131]     |

*BMMC, bone-marrow derived mast cell; OVA, ovalbumin; AR, allergic rhinitis; β-Hex, β-hexosaminidase; PGD₂, prostaglandin D₂; LTC₄, leukotriene C₄; IL-4, interleukin 4; IL-5, interleukin 5; IL-10, interleukin 10; IL-13, interleukin 13; TDI, Toluene-2, 4-diisocyanate; Bax, Bcl-2 Associated X Protein; SligE, human SARS-specific immunoglobulin; TNF-α, tumor necrosis factor α; SP, pulmonary surfactant associated protein; VCAM-1, vascular cell adhesion molecule-1; Pδ5, transcription factor pδ5; IFN-γ, interferon-gamma; Foxp3, forkhead box P3; IgE, immunoglobulin E; CD4, cluster of differentiation 4; IL-6, interleukin 6; IL-1β, interleukin 1 beta; MCP-1, monocyte chemoattractant protein; MIP-2, macrophage inflammatory protein; LIF, leukemia inhibitory factor; SPE, specific pathogen-free; GATA3, GATA binding protein 3; STAT6, signal transducer and activator of transcription 6; ICAM-1, intercellular adhesion molecule 1; COX-2, cyclooxygenase 2; SD, Sprague Dawley; MSC, mesenchymal stem cell; IgG1, immunoglobulin G1; T-bet, T-box-expressed-in-T-cells; p-STAT6, phospho-STAT6; SOCS1, suppressor of cytokine signaling 1; IgG2a, immunoglobulin G2a; LTE₄, Leukotriene E₄; ↑, up-regulation; ↓, down-regulation.
Table 7. Clinical trials.

| Classification | Compound/Extract | Source | Phase | Patients | Status | Registration Number | Reference |
|----------------|-----------------|--------|-------|----------|--------|---------------------|-----------|
| Plant          | Depigoid 50% Grasses/50% *Olea europaea* (2000DPP/mL), Depigoid 50% Grasses/50% *Parietaria judaica* (2000DPP/mL) | Grasses, *Olea europaea* L., *Parietaria judaica* L. | Phase 2 | 63 | Completed | NCT01734265 | [132] |
| Plant          | MK-3641 12 Amb a 1-U (short ragweed extract) MK-7243 2800 BAU (Timothy grass extract) | *Ambrosia artemisiifolia* L., *Phleum pratense* L. | Phase 4 | 102 | Completed | NCT02256553 | [133] |
| Plant          | Short ragweed pollen allergen extract | *Ambrosia artemisiifolia* L. | Phase 3 | 1025 | Completed | NCT02478398 | [134] |
| Plant          | SUBLIVAC FIX Birch | *Betula verrucosa* Ehrh. | Phase 2 | 269 | Completed | NCT01639768 | [135] |
| Plant          | SUBLIVAC FIX *Phleum pratense* | *Phleum pratense* L. | Phase 2 | 266 | Completed | NCT01682070 | [136] |
| Plant          | SUBLIVAC FIX *Phleum pratense* | *Phleum pratense* L. | Phase 2 | 168 | Completed | NCT02556801 | [137] |
| Animal         | German cockroach (*Blattella germanica*) allergenic extract | *Blattella germanica* | Phase 1 | 10 | Completed | NCT01221285 | [138] |
| Animal         | Mouse Allergenic Extract | *Mus musculus* | Phase 1 | 12 | Completed | NCT02532179 | [139] |
MK-3641 12 Amb a 1-U (short ragweed extract) and MK-7243 2800 BAU (timothy grass extract) were co-administered to patients [133]. Patients at least 18 years of age with ragweed and grass pollen-induced allergic rhinitis with or without conjunctivitis were recruited. After administration, the percentages of participants who experienced at least one event of local swelling were measured. During periods I, II, and III, they were 13.7%, 21.6%, and 14.7%, respectively. These results indicated that MK-3641 12 Amb a 1-U and MK-7243 2800 BAU are safe substances to treat AR.

The efficacy and safety of short ragweed pollen allergen extract sublingual immunotherapy tablets were assessed in children with ragweed-induced rhinoconjunctivitis with or without asthma [134]. The primary outcome was measured as the total combined score (TCS) during the peak ragweed season (RS). TCS is a daily symptom score (DSS) plus daily medication score (DMS), while RS means 15 consecutive days with the highest average pollen count. TCS could range from 0 to 38, and a lower score indicates fewer RC symptoms and medication use. TCS of short ragweed pollen allergen extract was 4.39 while the placebo was 7.12, thus implying short ragweed pollen allergen extract can be an effective treatment option for patients with rhinitis.

The optimal effective dose of SUBLIVAC FIX Birch was determined based on a decrease of upper airways reactivity after 5 months of treatment with different dosages of SUBLIVAC FIX Birch compared with placebo [135]. SUBLIVAC FIX Birch was administered in patients with allergic rhinitis/rhinoconjunctivitis caused by birch pollen. In all treatment groups, post-treatment symptom scores compared with baseline were improved. After active treatment, peak nasal inspiratory flow and serum IgG levels increased compared with placebo. All active dosages produced more adverse reactions than placebo, but those reactions were mainly mild and well-controlled.

Patients with allergic rhinitis/rhinoconjunctivitis caused by grass pollen were treated with SUBLIVAC FIX Phleum pratense [136]. This was a phase II, randomized, double-blind, and placebo-controlled study. The optimal effective dose of SUBLIVAC FIX Phleum pratense was determined with the same method as for SUBLIVAC FIX Birch. The dosages of five different pratense were 0, 3333, 10,000, 20,000, and 40,000 AUN/mL respectively. After 10 months, a study about SUBLIVAC FIX Phleum Pratense for grass pollen-allergic patients with IgE-mediated seasonal allergic rhinoconjunctivitis (ARC) was conducted. [137]. The safety and tolerability of the pratense were assessed, and the dose-response signal was measured by using the total symptom score (TSS). The TSS of SUBLIVAC FIX Phleum Pratense (SP) 10,000, 40,000, and 80,000 AUN/mL were 8.06, 8.19, and 7.69 while the score of placebo was 10.01, demonstrating that SP could be effective in relieving total symptoms of ARC.

A trial tested cockroach subcutaneous immunotherapy (SCIT) safety in cockroach-sensitive adults with asthma and/or perennial allergic rhinitis. (ICAC-18) [138]. No severe adverse effects related to treatment were reported.

Mouse allergenic extract, called mouse epithelial extract or allergenic extract of Mus musculus, was administered by subcutaneous injection in mouse-sensitive adults with asthma or/and perennial allergic rhinitis (ICAC-26) [139]. The primary objective of this study was to assess whether treatment with mouse subcutaneous immunotherapy (SCIT) is safe. A total of nine adverse events (AEs) were reported, and no serious adverse events (SAEs) were reported. Although further studies are required to ensure the safety of mouse allergenic extract, perhaps the number of adverse events shows that the extract treats rhinitis safely.

4. Discussion
4.1. Mechanisms of Natural Products Regulating AR Symptoms
4.1.1. T Helper Cell Differentiation

Diverse studies referred to T helper cell differentiation when discussing the process of how the target extract works to treat allergic rhinitis (Figure 2). There were twenty five plant-originated natural products and fourteen decoctions modulating T helper cell differentiation.
Figure 2. Schematic diagram of plants and decoctions that ameliorated allergic rhinitis by triggering T helper cell differentiation; BCE, Bupleurum chinense water extract; RMFE, Rosae Multiflorae Fructus water extract; BGPP, Brazilian green propolis; EGCG, Epigallocatechin gallate; DC, Dryopteris crassirhizoma.
IL-12, which is a Th1-related cytokine, was up-regulated by *Artemisia vulgaris* water extract, BCE, and RMFE [71,79,103]. Citrus, BCE, *Ostericum koreanum* root methanol extract, and Bu-Zhong-Yi-Qi-Tang showed their effects by increasing another Th1 cytokine, IFN-γ [60,66,79,117]. TNF-α is associated predominantly with Th1-mediated inflammation and is essential for the production of Th2 cytokines such as IL-4 and IL-12 [140]. The release of TNF-α was reduced by Chrysins, Citrus, *Els Holtzia ciliate* water extract, Gencydo®, *Ostericum koreanum* root methanol extract, *Lindera obtusiloba* water extract, Rosmarinic acid, Biyuanling, and KOB03 [58,60,61,63,64,66,68,116,122].

Th2 cytokines were the major route for regulation. Among plant-originated studies, *Albizia lebbeck* bark ethanol extract, *Artemisia vulgaris* water extract, Awa-tea leaf hot-water extract, BGPP, BGPP ethanol extract, BCE, Chrysins, Royal jelly, EGCG, *Ostericum koreanum* root methanol extract, RMFE, *Spinacia oleracea* Linn. aqueous extract, and *Wild grape* hot-water extract ameliorated allergic rhinitis by inhibiting IL-4 [55–58,66,69,71,72,79,86,103,104]. Among extract studies, Ethanol extract of Biyeom-Tang, Biyuanling, Bu-Zhong-Yi-Qi-Tang, Hyeonggaeyeongyotang, Mahuang Fuzi Xixin decoction, Paeoniae-cinnamomi-Root extract, Qi-fang-bi-min-tang, Shenqi, So-Cheong-Ryong-Tang, and Yiqi Wenyang Fang reduced IL-4 expression [114–118,124–126,128,131]. Furthermore, IL-5 was inhibited by *Albizia lebbeck* bark ethanol extract, *Artemisia vulgaris* water extract, BGPP, BGPP ethanol extract, BCE, Citrus, Royal jelly, RMFE, *Syzygium formosum* leaf extract, and Wild grape hot-water extract [55–57,60,71,72,79,103,104]. Ethanol extract of Biyeom-Tang, Gami-hyunggyeyeongyotang, and Tong Qiao nose drop also suppressed expression of IL-5 [111,115,129]. There were 7 plant extracts and 7 decoctions that modulated IgE levels. *Cinnamomum zeylanicum* bark hydroalcoholic extract, DC, Gencydo®, *Glycine max* water extract, *Ostericum koreanum* root methanol extract, *Piper nigrum* L. extract, and *Spinacia oleracea* Linn. aqueous extract down-regulated IgE levels [63,66,83,85,89,93,104]. Bu-Zhong-Yi-Qi-Tang, Gami-hyunggyeyeongyotang, KOB03, Mahuang Fuzi Xixin decoction, Shenqi, Senn-kinn-naidaku-sann, and So-Cheong-Ryong-Tang prohibited IgE production [111,113,114,117,122,124,128].

IL-6, which is a Th17-related cytokine, was suppressed by seven plant extracts. Chrysins, *Els Holtzia ciliate* water extract, EGCG, *Ostericum koreanum* root methanol extract, *Lindera obtusiloba* water extract, Rosmarinic acid, and *Piper nigrum* L. extract mediated allergic reactions by down-regulating IL-6 [58,61,64,66,68,86,93].

Berberine and Bu-Zhong-Yi-Qi-Tang increased Foxp3, which transits Th0 cells to Treg cells and ameliorates allergic symptoms [77,117].

4.1.2. Histamine Receptors

There were six plant-originated studies discussing histamine receptor functions (Figure 3). H1R was down-regulated by *Albizia lebbeck* bark ethanol extract, BGPP, enzyme-treated Royal jelly, and wild grape [55,56,72]. *Cinnamomum zeylanicum* bark hydroalcoholic extract and *Lindera obtusiloba* water extract reduced histamine release [64,83]. *Albizia lebbeck* bark ethanol extract regulated histidine decarboxylase [55].

4.1.3. 5-Lipooxygenase Pathway and Prostaglandin E2 Synthesis-and-Signaling Pathway

Two plant-originated natural products, three minerals, and three decoction studies discussed the 5-lipoxygenase pathway (Figure 4). MAPK and NF-kB were suppressed by *Els Holtzia ciliate* water extract [61]. EGCG regulated COX-2, thus reducing allergic symptoms [86]. CysLT1 receptor activation was down-regulated by *Ganoderma lucidum* powder [110]. LTC₄ was suppressed by Kuji amber, Kujiamberol, and ethanol extract of Biyeom-Tang [106,115]. Mahuang Fuzi Xixin decreased PGE₂, and Xingbi gel regulated the secretion of LTE₄ [112,130].
4.1.3. 5-lipooxygenase Pathway and Prostaglandin E2 Synthesis-and-Signaling Pathway

Two plant-originated natural products, three minerals, and three decoction studies discussed the 5-lipooxygenase pathway (Figure 4). MAPK and NF-κB were suppressed by Elsholtzia ciliata water extract [61]. EGCG regulated COX-2, thus reducing allergic symptoms [86]. CysLT1 receptor activation was down-regulated by Ganoderma lucidum powder [110]. LTC4 was suppressed by Kuji amber, Kujigamberol, and ethanol extract of Biyeom-Tang [106,115]. Mahuang Fuzi Xixin decreased PGE2, and Xingbi gel regulated the secretion of LTE4 [112,130].
4.1.4. Immune Response Pathways

There were eleven studies regarding plant-originated natural products and three decoction studies discussing histamine receptors’ functions in immune responses (Figure 5). p-Akt was regulated by Ortho-vanillic acid and Perilla-derived methoxylflavanone [65,67]. NF-κB was inhibited by Chrysin, *Elsholtzia ciliata* water extract, *Lindera obtusiloba* water extract, Rosmarinic acid, Perilla frutescens var. acuta Kudo 30% ethanol extract powder, and Piper nigrum L. extract [58,61,64,68,93]. p-IkBα was reduced by *Elsholtzia ciliata* water extract, *Lindera obtusiloba* water extract, and *Ostericum koreanum* root methanol extract [61,64,66]. p-Lyn and p-Syk are regulated by Ortho-vanillic acid [65]. The treatment of *Ostericum koreanum* root methanol extract suppressed MAPKs [66]. Perilla frutescens var. acuta Kudo 30% ethanol extract powder ameliorated allergic inflammatory reactions by decreasing Ca²⁺ [68]. Enzyme-treated Royal jelly and wild grape hot-water extract inhibited the expression of p-PKCδ [56,72]. Chrysin, Epigallocatechin gallate, Rosmarinic acid, Perilla frutescens var. acuta Kudo, Piper nigrum L. extract, Gami-hyunggyeyeongyotang, KOBO3, and So-Cheong-Ryong-Tang regulated IL-1β [58,68,86,93,118,122,127].

![Figure 5](image_url)

**Figure 5.** Various pathways for immune response. PIP₂, phosphatidyl inositol 4, 5-trisphosphate; PIP₃, phosphatidylinositol 3, 4, 5-trisphosphate; P, phosphate; NF-κB, p65 nuclear factor kappa B; BCR, B cell receptor; Ig, immunoglobulin; Syk, spleen tyrosine kinase; BKT, Bruton’s tyrosine kinase; PLCγ₂, phospholipase C gamma 2; IL, interleukin; IL-R, interleukin receptor; MAPK, mitogen-activated protein kinase; NF-AT, nuclear factor of activated T-cells.

4.2. Comparison Analysis

Some compounds or extracts were examined in more than one study. There were two different studies about BGPP. The studies differed in experimental subjects, dose, duration, mechanism, and efficacy of the extract. Shaha et al. used HeLa cells, RBL-2H3 cells, and a TDI-sensitized rat model, while Tani et al. used Cry j1-treated PBMCs and Cry j1-treated peripheral leukocytes of allergic patients [56,57]. The former study showed the relationship between improvement of nasal symptoms and degradation of H1R mRNA, p-PKCδ, IL-9, IL-4, and IL-5; the latter explained that nasal obstruction preventing property of BGPP was related to degradation of IL-5, IL-14, and CysLTs. Two different studies...
examined the extract of Piper nigrum L. (PNE) as AR treatment in vivo [90,93]. Bui et al. and Bang et al. both used OVA-induced AR mice, but the species differed—BALB/c mice and Swiss albino mice, respectively. The former administered 50, 100, and 200 mg/kg of PNE and the latter 10, 20, and 40 mg/kg. Bui et al. compared the efficacy of PNE with that of Dex, while Bang et al. did so with montelukast. Different mechanisms related to AR symptoms were investigated: the former focused on the inhibition of STAT3 and NFκBp65 plus the elevation of Th1, whereas the latter focused on the inhibition of IL-6, IL-1β, and IgE. KOB03 was examined by various methods [122,141]. OVA-induced AR BALB/c mice and SD rats were administered with 100 or 200 mg/kg of KOB03 for 7 days. The efficacy of the decoction was generated by inhibiting TNF-α, IL-1β, IL-6, and IL-8. In comparison, only OVA-induced AR BALB/c mice were administered with a higher dose, 5 mg/kg, for 8 days. As a result, the decrease of IgE, LTC₄, IL-4, and IL-1β inhibited nasal inflammation. Ren et al. and Tang et al. examined the efficacy of the Mahuang Fuzi Xixin Decoction respectively [112,124]. Ren et al. conducted in vivo experiment using OVA-induced AR SPF Wi star rats, while Tang et al. organized an in vitro experiment. Ku et al. and Mo et al. experimented with different doses and durations of So-Cheong-Ryong-Tang: 20 mg/mL for 14 days and 1 g/kg for 7 days, respectively [127,128].

4.3. Limitations

The reviewed studies had some limitations. There were experiments with high doses (over 60 µg/mL in vitro) of the compound or extract [56,57,61,62,111,114]. Some experiments were conducted only in vitro [57,58,60–63,66,67,70,106]. The nasal symptoms and pathogenesis observed in the studies using the TDI-sensitized rhinitis model may differ from AR, an IgE mediated disease, as TDI-sensitized rhinitis is a non-IgE mediated disease [55,56,72,89,116,142]. Furthermore, this paper had shortcomings that should be remedied in the following studies. The papers are predominantly about compounds and extracts that originated from plants. Clinical trials lack quantity compared with in vivo and in vitro experiments, eight to a total of forty-nine. Additionally, this review was limited to studies published in the last 10 years and written in English. Above all, although a variety of compounds and extracts were included, examination for each of them was insufficient.

4.4. Significance

This review included specific mechanisms of AR and its treatment, examined the result of diverse research, and contains specific figures of AR mechanisms. As various compounds and extracts were reviewed, this paper details the potential for the widespread use of natural products in treating AR. Further studies about toxicity, stability, and pharmacokinetics based on this review could be conducted to confirm their possibilities.

5. Methods

Relevant articles published between 2009 and 2019 regarding the therapeutic effect of plant extracts on allergic rhinitis were collected from PUBMED, the Google Scholar database, and the Web of Science. The search algorithm was designed by entering related keywords such as ‘allergic rhinitis’, ‘natural product’, ‘herbal medicine’, ‘decoction’, ‘tang’, ‘extract’, and ‘clinical trial’. We only reviewed articles written in English and excluded duplicates and studies with English abstracts but non-English articles. The papers were first classified into two categories based on the form of the experimental model: in vivo and in vitro. Then, we reclassified in vitro studies into three categories according to the kinds of natural resources used in the experiment: plant, etc., and decoction. “Etc.” includes animal and fungi, which were very few in number to be exclusively classified. For data unity and a better understanding of the influence of compounds on allergic rhinitis, we only considered single compounds except for decoction. Decoctions were included for the inclusiveness of the study; plant extracts are frequently used in clinical situations in the form of decoction or tang. Overall, fifty-seven studies demonstrating the efficacy of using plant extracts in treating nasal inflammation were reviewed.
6. Conclusions

Natural products can be used as an effective treatment for AR. In most of the studies reviewed, they showed positive effects on relieving the symptoms of AR, such as rubbing of the nose and sneezing, or inhibiting inflammation in vivo and in vitro. The results of clinical trials showed that the treatments were effective and safe. Therefore, natural products could be attractive candidates for drug development for treating AR.

Author Contributions: Investigation, S.L., I.J., J.C. and C.S.; data curation, S.L., I.J., J.C., C.S. and B.K.; writing—original draft preparation, S.L., I.J., J.C. and C.S.; writing—review and editing, S.L., I.J., K.-I.K., B.-S.S., S.-G.K. and B.K.; visualization, S.L., J.C. and C.S.; supervision, B.K.; project administration, B.K.; funding acquisition, S.-G.K. and B.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2020R1I1A2066686), the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2020R1A5A201941311).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Bartle, J. Patient education in the effective management of hay fever. Nurs. Stand. 2016, 30, 48–53. [CrossRef] [PubMed]
2. Brožek, J.L.; Bousquet, J.; Agache, I.; Agarwal, A.; Bachert, C.; Bosnic-Anticevich, S.; Brignardello-Petersen, R.; Canonica, G.W.; Casale, T.; Chavannes, N.H. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. J. Allergy Clin. Immunol. 2017, 140, 950–958. [CrossRef]
3. Galli, S.J.; Tsai, M. IgE and mast cells in allergic disease. Nat. Med. 2012, 18, 693–704. [CrossRef]
4. Bousquet, J.; Van Cauwenberge, P.; Khaltaev, N. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. 2001, 108, S147–S334. [CrossRef]
5. May, J.R.; Dolen, W.K. Management of allergic rhinitis: A review for the community pharmacist. Clin. Ther. 2017, 39, 2410–2419. [CrossRef]
6. Seidman, M.D.; Gurgel, R.K.; Lin, S.Y.; Schwartz, S.R.; Baroody, F.M.; Bonner, J.R.; Dawson, D.E.; Dykewicz, M.S.; Hackell, J.M.; Han, J.K. Clinical practice guideline: Allergic rhinitis. Otolaryngol.–Head Neck Surg. 2015, 152, S1–S43. [CrossRef]
7. Greiner, A.N.; Hellings, P.W.; Rotiniot, G.; Scadding, G.K. Allergic rhinitis. Lancet 2011, 378, 2112–2122. [CrossRef]
8. Mygind, N. Allergic rhinitis. In History of Allergy; Karger Publishers: Basel, Switzerland, 2014; Volume 100, pp. 62–68. [CrossRef]
9. Dipiro, J.T.; Talbert, R.L.; Yee, G.C.; Matzke, G.R.; Wells, B.G.; Posey, L.M. Pharmacotherapy: A Pathophysiologic Approach, ed; McGraw-Hill Medical: New York, NY, USA, 2014.
10. Lipworth, B.J.; Jackson, C.M. Safety of inhaled and intranasal corticosteroids. Drug Saf. 2000, 23, 11–33. [CrossRef]
11. Lin, L.; Luo, L.; Zhong, M.; Xie, T.; Liu, Y.; Li, H.; Ni, J. Gut microbiota: A new angle for traditional herbal medicine research. RSC Adv. 2019, 9, 17457–17472. [CrossRef]
12. Srivastava, R.; Srivastava, S.; Singh, S.P. Comparative study of anti-allergic activity of two poly-herbal formulations in ova-challenged allergic rhinitis mice model. Orient. Pharm. Exp. Med. 2019, 19, 37–47. [CrossRef]
13. Bernardini, S.; Tiezzi, A.; Laghezza Masci, V.; Volidi, E. Natural products for human health: An historical overview of the drug discovery approaches. Nat. Prod. Res. 2018, 32, 1926–1950. [CrossRef]
14. David, B.; Wolfender, J.-L.; Dias, D.A. The pharmaceutical industry and natural products: Historical status and new trends. Phytochem. Rev. 2015, 14, 299–315. [CrossRef]
15. Platts-Mills, T.A. The role of immunoglobulin E in allergy and asthma. Am. J. Respir. Crit. Care Med. 2001, 164, S1–S5. [CrossRef] [PubMed]
16. Ishizaka, K.; Ishizaka, T.; Lee, E.H. Biologic function of the Fc fragments of E myeloma protein. Immunochemistry 1970, 7, 687–702. [CrossRef]
17. Metzger, H.; Alcaraz, G.; Hohman, R.; Kinet, J.; Pribyl, V.; Quarto, R. The receptor with high affinity for immunoglobulin E. Annu. Rev. Immunol. 1986, 4, 419–470. [CrossRef]
18. Bieber, T.; De La Salle, H.; Wollenberg, A.; Hakimi, J.; Chizzonite, R.; Ring, J.; Hanau, D.; De la Salle, C. Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI). J. Exp. Med. 1992, 175, 1285–1290. [CrossRef]
19. Wang, B.; Rieger, A.; Kilgus, O.; Ochiai, K.; Maurer, D.; Födinger, D.; Kinet, J.; Stingl, G. Epidermal Langerhans cells from normal human skin bind monomeric IgE via Fc epsilon RI. J. Exp. Med. 1992, 175, 1353–1365. [CrossRef] [PubMed]
Antioxidants 2021, 10, 1524

49. Opene, M.; Kuratsin-Mills, J.; Husain, S.; Ibe, B.O. Sickle erythrocytes and platelets augment lung leukotriene synthesis with downregulation of anti-inflammatory proteins: Relevance in the pathology of the acute chest syndrome. Palm. Circ. 2014, 4, 482–495. [CrossRef]

50. Brodie, E.J.; Infantino, S.; Low, M.S.Y.; Tarlington, D.M. Lyn, Lupus, and (B) Lymphocytes, a Lesson on the Critical Balance of Kinase Signaling in Immunity. Front. Immunol. 2018, 9, 401. [CrossRef]

51. Reth, M. Antigen receptor tail clue. Nature 1989, 338, 383–384. [CrossRef] [PubMed]

52. Lee, S.J.; Kim, S.J.; Lee, H.-S.; Kwon, O.-S. PKCβ mediates NF-κB inflammatory response and downregulates SIRT1 expression in liver fibrosis. J. Int. Mol. Sci. 2019, 20, 4607. [CrossRef]

53. Carpenter, L.; Cordery, D.; Biden, T.J. Protein kinase C delta activation by interleukin-1β stabilizes inducible nitric-oxide synthase mRNA in pancreatic beta-cells. J. Biol. Chem. 2001, 276, 5368–5374. [CrossRef]

54. Willingham, S.B.; Allen, I.C.; Bergstrahl, D.T.; Brickey, W.J.; Huang, M.T.-H.; Taxman, D.J.; Duncan, J.A.; Ting, J.P.-Y. NLRP3 (NALP3, Cryopyrin) Facilitates In Vivo Caspase-1 Activation, Necrosis, and HMGB1 Release via Inflammsome-Dependent and -Independent Pathways. J. Immunol. 2009, 183, 2008–2015. [CrossRef] [PubMed]

55. Nurul, I.M.; Mizuguchi, H.; Shahriar, M.; Venkatesh, P.; Maeyama, K.; Mukherjee, P.K.; Hattori, M.; Choudhuri, M.S.; Takeda, N.; Fukui, H. Albizia lebbbeck suppresses histamine signaling by the inhibition of histamine H1 receptor and histidine decarboxylase gene transcriptions. Int. Immunopharmacol. 2011, 11, 1766–1772. [CrossRef]

56. Shaha, A.; Mizuguchi, H.; Kitamura, Y.; Fujino, H.; Yabumoto, M.; Takeda, N.; Fukui, H. Effect of Royal Jelly and Brazilian Green Propolis on the Signaling for Histamine H1 Receptor and Interleukin-9 Gene Expressions Responsible for the Pathogenesis of the Allergic Rhinitis. Biol. Pharm. Bull. 2018, 41, 1440–1447. [CrossRef]

57. Tani, H.; Hasumi, K.; Tatetufu, T.; Hashimoto, K.; Koshino, H.; Takahashi, S. Inhibitory activity of Brazilian green propolis components and their derivatives on the release of cysteuletokines. Bioorg. Med. Chem. 2010, 18, 151–157. [CrossRef] [PubMed]

58. Bae, Y.; Lee, S.; Kim, S.H. Chrysins suppresses mast cell-mediated allergic inflammation: Involvement of calcium, caspase-1 and nuclear factor-kappaB. Toxicol. Appl. Immunol. 2011, 254, 56–64. [CrossRef] [PubMed]

59. De Bruin, A.; Baars, E. Citrus/Cydonia Comp. Use in General Practice. A Survey among Anthroposophic Physicians; Louis Bolk Instituut: Driebergen, The Netherlands, 2001; p. 50.

60. Baars, E.W.; Jong, M.C.; Boers, I.; Nierop, A.F.; Savelkouil, H.F. A comparative in vitro study of the effects of separate and combined products of Citrus e fructibus and Cydonia e fructibus on immunological parameters of seasonal allergic rhinitis. Mediat. Inflamm. 2012, 2012, 109829. [CrossRef] [PubMed]

61. Kim, H.H.; Yoo, J.S.; Lee, H.S.; Kwon, T.K.; Shin, T.Y.; Kim, S.H. Elsholtzia ciliata inhibits mast cell-mediated allergic inflammation: Role of calcium, p38 mitogen-activated protein kinase and nuclear factor-[kappa]B. Exp. Biol. Med. (Maywood) 2011, 236, 1070–1077. [CrossRef] [PubMed]

62. Grundemann, C.; Papagiannopoulos, M.; Lamy, E.; Mersch-Sundermann, V.; Huber, R. Immunomodulatory properties of a lemon-derivative from the Asian medicinal herb (Perilla frutescens) potently suppresses IgE-mediated immediate hypersensitivity reactions. Acta Pharm. Sin. 2011, 51, 43–50. [CrossRef] [PubMed]

63. Steiert, S.A.; Zissler, U.M.; Chaker, A.M.; Esser-von-Bieren, J.; Dittlein, D.; Guerth, F.; Jakwerth, C.A.; Piontek, G.; Zahner, C.; Drewe, J.; et al. Anti-inflammatory effects of the petasin phyto drug Ze339 are mediated by inhibition of the STAT pathway. Int. J. Mol. Med. 2011, 28, 338–348. [CrossRef] [PubMed]

64. Jung, H.W.; Jung, J.K.; Park, Y.K. Antiallergic effect of Ostericum koreanum root extract on ovalbumin-induced allergic rhinitis mouse model and mast cells. Asian Pac. J. Allergy Immunol. 2011, 29, 338–348.

65. Kamei, R.; Fujimura, T.; Matsuda, M.; Kakihara, K.; Hirakawa, N.; Baba, K.; Ono, K.; Arakawa, K.; Kawamoto, S. A flavanone derivative from the Asian medicinal herb (Perilla frutescens) potently suppresses IgE-mediated immediate hypersensitivity reactions. Biochem. Biophys. Res. Commun. 2017, 483, 674–679. [CrossRef] [PubMed]

66. Oh, H.A.; Park, C.S.; Ahn, H.J.; Park, Y.S.; Kim, H.M. Effect of Perilla frutescens var. acuta Kudo and rosmarinic acid on allergic inflammatory reactions. Exp. Biol. Med. (Maywood) 2011, 236, 99–106. [CrossRef] [PubMed]

67. Heo, J.C.; Park, C.S.; Lee, H.J.; Kim, S.O.; Kim, T.H.; Lee, S.H. Amelioration of asthmatic inflammation by an aqueous extract of mugwort pollen desensitizes specific allergen-induced allergy in mice. Vaccine 2011, 30, 1437–1444. [CrossRef] [PubMed]

68. Islam, R.; Mizuguchi, H.; Shaha, A.; Nishida, K.; Yabumoto, M.; Ikeda, H.; Fujino, H.; Kitamura, Y.; Fukui, H.; Takeda, N. Effect of wild grape on the signaling of histamine H1 receptor gene expression responsible for the pathogenesis of allergic rhinitis. J. Med. Investig. 2018, 65, 242–250. [CrossRef]

69. Hu, Z.; Jiao, Q.; Ding, J.; Liu, F.; Liu, R.; Shan, L.; Zeng, H.; Zhang, J.; Zhang, W. Berberine induces dendritic cell apoptosis and has therapeutic potential for rheumatoid arthritis. Arthritis Rheum. 2011, 63, 949–959. [CrossRef]
74. Cui, G.; Qin, X.; Zhang, Y.; Gong, Z.; Ge, B.; Zang, Y.Q. Berberine differentially modulates the activities of ERK, p38 MAPK, and JNK to suppress Th17 and Th1 T cell differentiation in type 1 diabetic mice. J. Biol. Chem. 2009, 284, 28420–28429. [CrossRef]

75. Qin, X.; Guo, B.T.; Wan, B.; Fang, L.; Lu, L.; Wu, L.; Zang, Y.Q.; Zhang, J.Z. Regulation of Th1 and Th17 cell differentiation and amelioration of experimental autoimmune encephalomyelitis by natural product compound berberine. J. Immunol. 2010, 185, 1855–1863. [CrossRef]

76. Ma, X.; Jiang, Y.; Wu, A.; Chen, X.; Pi, R.; Liu, M.; Liu, Y. Berberine attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice. PLoS ONE 2010, 5, e13489. [CrossRef]

77. Kim, B.Y.; Park, H.R.; Jeong, H.G.; Kim, S.W. Berberine reduce allergic inflammation in a house dust mite allergic rhinitis mouse model. Rhinology 2015, 53, 353–358. [CrossRef]

78. Sun, H.-X. Haemolytic activities and adjuvant effect of Bupleurum chinense saponins on the immune responses to ovalbumin in mice. Vaccine 2006, 24, 1324–1331. [CrossRef] [PubMed]

79. Bui, T.T.; Piao, C.H.; Hyeon, E.; Fan, Y.; Choi, D.W.; Jung, S.Y.; Song, C.H.; Chai, O.H. Preventive Effect of Bupleurum chinense on Nasal Inflammation via Suppressing T Helper Type 2, Eosinophil and Mast Cell Activation. Am. J. Chin. Med. 2019, 47, 405–421. [CrossRef] [PubMed]

80. Kirtikar, K.; Basu, B. Indian Medicinal Plants; LM Basu: Allahabad, India, 1975.

81. Warrier, P.K. Indian Medicinal Plants: A Compendium of 500 Species; Orient Blackswan: Andhra Pradesh, India, 1993; Volume 5.

82. Khory, R.N.; Katrak, N.N. Materica Medica of India and Their Therapeutics; Times of India Press: Mumbai, India, 1903.

83. Aswar, U.M.; Kandhare, A.D.; Mohan, V.; Thakurdesai, P.A. Anti-inflammatory effect of intranasal administration of type-A procyanidin polyphenols based standardized extract of cinnamon bark in ovalbumin sensitized BALB/c mice. Phytother. Res. 2015, 29, 423–433. [CrossRef] [PubMed]

84. Chang, S.-H.; Bae, J.-H.; Hong, D.-P.; Choi, K.-D.; Kim, S.-C.; Her, E.; Kim, S.-H.; Kang, C.-D. Dryopteris crassirhiza has anti-cancer effects through both extrinsic and intrinsic apoptotic pathways and G0/G1 phase arrest in human prostate cancer cells. J. Ethnopharmacol. 2010, 130, 248–254. [CrossRef]

85. Piao, C.H.; Kim, T.G.; Bui, T.T.; Song, C.H.; Shin, D.U.; Eom, J.E.; Lee, S.Y.; Shin, H.S.; Chai, O.H. Ethanol extract of Dryopteris crassirhiza alleviates allergic inflammation via inhibition of Th2 response and mast cell activation in a murine model of allergic rhinitis. J. Ethnopharmacol. 2019, 232, 21–29. [CrossRef]

86. Fu, M.; Fu, S.; Ni, S.; Zou, L.; Liu, Y.; Hong, T. Anti-inflammatory effect of epigallocatechin gallate in a mouse model of ovalbumin-induced allergic rhinitis. Int. Immunopharmacol. 2017, 49, 102–108. [CrossRef]

87. Mateos-Aparicio, I.; Cuenca, A.R.; Villanueva-Suárez, M.; Zapata-Revilla, M. Soybean, a promising health source. Nutr. Hosp. 2008, 23, 305–312.

88. Lund, C.O.; Mortensen, A.; Nilas, L.; Breinholt, V.M.; Larsen, J.-J.; Ottesen, B. Estrogen and phytoestrogens: Effect on eNOS expression and in vitro vasodilation in cerebral arteries in ovariectomized Watanabe heritable hyperlipidemic rabbits. Eur. J. Obstet. Gynecol. Reprod. Biol. 2007, 130, 85–89. [CrossRef]

89. Katayanagi, Y.; Yasui, K.; Ikemoto, H.; Taguchi, K.; Fukutomi, R.; Isemura, M.; Nakayama, T.; Imai, S. The clinical and immunomodulatory effects of green soybean extracts. Food Chem. 2013, 138, 2300–2305. [CrossRef]

90. Bang, J.S.; Choi, H.M.; Sur, B.-J.; Lim, S.-J.; Kim, J.Y.; Yang, H.-I.; Yoo, M.C.; Hahn, D.-H.; Kim, K.S. Anti-inflammatory and antiallergic effect of Piper nigrum fruit extract in an ovalbumin-induced allergic rhinitis by targeting of NFκBp65 and STAT3 signalings. Biomed. Pharm. 2019, 53, 1358–1366. [CrossRef] [PubMed]

91. Bui, T.T.; Piao, C.H.; Hyeon, E.; Fan, Y.; Jung, S.Y.; Cho, D.W.; Lee, S.Y.; Shin, H.S.; Song, C.H.; Chai, O.H. The protective role of Piper nigrum fruit extract in an ovalbumin-induced allergic rhinitis. J. Immunol. 2009, 182, 21–29. [CrossRef] [PubMed]

92. Meghwal, M.; Goswami, T. Piper nigrum and piperine: An update. Crit. Rev. Food Sci. Nutr. 2013, 53, 875–886. [CrossRef] [PubMed]

93. Bui, T.T.; Piao, C.H.; Hyeon, E.; Fan, Y.; Van Nguyen, T.; Jung, S.Y.; Choi, D.W.; Lee, S.Y.; Shin, H.S.; Song, C.H.; et al. The anti-cancer effects through both extrinsic and intrinsic apoptotic pathways and G0/G1 phase arrest in human prostate cancer cells. J. Ethnopharmacol. 2010, 130, 248–254. [CrossRef]

94. Aswar, U.; Shintre, S.; Chepurwar, S.; Aswar, M. Antiallergic effect of piperine on ovalbumin-induced allergic rhinitis in mice. Biol. Pharm. Biomed. 2008, 53, 1358–1366. [CrossRef] [PubMed]

95. Pereira, A.D.S.; Seixas, F.R.M.S.; Aquino Neto, F.R. Propolis: 100 anos de pesquisa e suas perspectivas futuras. Quimica Nova 2002, 25, 321–326. [CrossRef] [PubMed]

96. Wollenweber, E.; Hausen, B.; Greenaway, W. Phenolic constituents and sensitizing properties of propolis, poplar balsam and balsam of Peru. Bull. Liaison-Groupe Polyphen. 1990, 15, 112–120.

97. Dimov, V.; Ivanovska, N.; Bankova, V.; Popov, S. Immunomodulatory action of propolis: IV. Prophylactic activity against gram-negative infections and adjuvant effect of the water-soluble derivative. Vaccine 1992, 10, 817–823. [CrossRef]

98. Marcucci, M.C. Propolis: Chemical composition, biological properties and therapeutic activity. Apidologie 1995, 26, 83–99. [CrossRef]

99. Shimizu, T.; Hino, A.; Tsutsumi, A.; Park, Y.K.; Watanabe, W.; Kurokawa, M. Anti-influenza virus activity of propolis in vitro and its efficacy against influenza infection in mice. Antivir. Chem. Chemother. 2008, 19, 7–13. [CrossRef] [PubMed]

100. Park, Y.K.; Koo, M.H.; Abreu, J.A.; Ikegaki, M.; Cury, J.A.; Rosalen, P.L. Antimicrobial activity of propolis on oral microorganisms. Curr. Microbiol. 1998, 36, 24–28. [CrossRef]
101. Yasar, M.; Savranlar, Y.; Karaman, H.; Sagit, M.; Silici, S.; Ozcan, I. Effects of propolis in an experimental rat model of allergic rhinitis. *Am. J. Otolaryngol.* 2016, 37, 287–293. [CrossRef]

102. Song, C.H.; Bui, T.T.; Piao, C.H.; Shin, H.S.; Shon, D.-H.; Han, E.-H.; Kim, H.T.; Chai, O.H. Rosae Multiflorae fructus hot water extract inhibits a murine allergic asthma via the suppression of Th2 cytokine production and histamine release from mast cells. *J. Med. Food* 2016, 19, 853–859. [CrossRef]

103. Bui, T.T.; Kwon, D.A.; Choi, D.W.; Jung, S.Y.; Lee, S.Y.; Piao, C.H.; Hyeon, E.; Fan, Y.; Yeon, S.H.; Son, R.H.; et al. Rosae multiflorae fructus extract and its four active components alleviate ovalbumin-induced allergic inflammatory responses via regulation of Th1/Th2 imbalance in BALB/c mice. *Phytomedicine* 2019, 55, 238–248. [CrossRef] [PubMed]

104. Nguyen, T.M.N.; Lomonova, M.; Vu, T.P.D.; Le, B.V.; Kim, Y.H.; Kang, J.S.; Hwang, I. Anti-allergic effects of the ethanol extract of Syzygium formosum (Wall.) Masam leaves and its immunoregulatory mechanisms. *J. Ethnopharmacol.* 2018, 211, 171–179. [CrossRef]

105. Zhuang, Y.; Qin, K.; Yu, B.; Liu, X.; Cai, B.; Cai, H. A metabolomics research based on UHPLC-ESI-Q-TOF-MS coupled with metabolic pathway analysis: Treatment effects of stir-frying Xanthii Fructus on allergic rhinitis in mice model. *Biomed. Chromatogr.* 2018, 32, e4352. [CrossRef] [PubMed]

106. Maruyama, M.; Kobayashi, M.; Uchida, T.; Shimizu, E.; Higashio, H.; Ohno, M.; Uesugi, S.; Kimura, K.I. Anti-allergy activities of Kuji amber extract and kuji gamberol. *Fitoterapia* 2019, 127, 263–270. [CrossRef] [PubMed]

107. Kimura, Y.; Taniguchi, M.; Baba, K. Antitumor and antimetastatic effects on liver of triterpenoid fractions of Ganoderma lucidum: Mechanism of action and isolation of an active substance. *Anticancer Res.* 2002, 22, 3309–3318. [PubMed]

108. Maruyama, H.; Yamazaki, K.; Murofushi, S.; Konda, C.; Ikekawa, T. Antitumor activity of *Sarcodon aspratus* (Berk.) S. Ito and *Ganoderma lucidum* (Fr.) Karst. *J. Pharm.* 1999, 12, 118–123. [CrossRef]

109. Min, B.S.; Gao, J.J.; Nakamura, N.; Hattori, M. Triterpenes from the spores of *Ganoderma lucidum* and their cytotoxicity against meth-A and LLC tumor cells. *Chem. Pharm. Bull. (Tokyo)* 2000, 48, 1026–1033. [CrossRef] [PubMed]

110. Mizutani, N.; Nabe, T.; Shimazu, S.; Yoshino, S.; Kohno, S. Effect of *Ganoderma lucidum* on pollen-induced biphasic nasal blockage in a guinea pig model of allergic rhinitis. *Phytother. Res.* 2012, 26, 325–332. [CrossRef] [PubMed]

111. Im, Y.S.; Lee, B.; Kim, E.Y.; Min, J.H.; Song, D.U.; Lim, J.M.; Eom, J.W.; Cho, H.J.; Sohn, Y.; Jung, H.S. Antiallergic effect of *Rosae multiflorae* hot water prescription inhibits allergic rhinitis in mice. *Immunopharmacol. Immunotoxicol.* 2004, 26, 765–769. [CrossRef] [PubMed]

112. Song, C.H.; Bui, T.T.; Lee, S.Y.; Chai, O.H. Rosae Multiflorae fructus hot water extract and its four active components alleviate ovalbumin-induced allergic inflammatory responses via regulation of Th1/Th2 imbalance in BALB/c mice. *Phytomedicine* 2019, 55, 238–248. [CrossRef] [PubMed]

113. Shao, Y.Y.; Zhou, Y.M.; Hu, M.; Li, J.Z.; Chen, C.J.; Wang, Y.J.; Shi, X.Y.; Wang, W.J.; Zhang, T.T. The Anti-Allergic Rhinitis Effect of Biyeom-Tang on mast cells and allergic rhinitis. *BMC Complement. Altern. Med.* 2015, 52, 252–259. [CrossRef] [PubMed]

114. Won Jung, H.; Jung, J.K.; Weon Cho, C.; Kang, J.S.; Park, Y.K. Antiallergic effect of KOB03, a polyherbal medicine, on mast cell-mediated allergic responses in ovalbumin-induced allergic rhinitis mouse and human mast cells. *Arch. Pharmacal Res.* 2018, 32, e4352. [CrossRef] [PubMed]

115. Xiang, M.; Wu, L.; Su, H.; Han, H.; Xiao, X.; Yin, X.; Fan, Y.; Zhang, L.; Huang, Y.; et al. *Biyuanling* suppresses the toluene-2, 4-diisocyanate induced allergic rhinitis in guinea pigs. *Oncotarget* 2018, 9, 12620–12629. [CrossRef]

116. Xie, M.Q.; Liu, J.; Long, Z.; Tian, D.F.; Zhao, C.Q.; Yang, P.C. Modulation of immune tolerance with a Chinese traditional prescription inhibits allergic rhinitis in mice. *N. Am. J. Med. Sci.* 2011, 3, 503–507. [PubMed]

117. Huang, Y.; Tan, X.; Chen, F.; Xing, X.; Huang, Y.; Tan, X. Mahuang Fuzi Xixin Decoction Attenuates Th1 and Th2 Responses in ovalbumin-induced allergic rhinitis model. *Mediat. Inflamm.* 2014, 2014, 418075. [CrossRef]

118. Hong, S.H.; Kim, S.R.; Choi, H.S.; Ku, J.M.; Soo, H.S.; Shin, Y.C.; Ko, S.G. Effects of Hyeonggayeeyongyo-tang in ovalbumin-induced allergic rhinitis model. *Mediat. Inflamm.* 2014, 2014, 418075. [CrossRef]

119. Jeong, K.T.; Kim, S.G.; Lee, J.; Park, Y.N.; Park, H.H.; Park, N.Y.; Kim, K.J.; Lee, H.; Lee, Y.J.; Lee, E. Anti-allergic effect of a Korean traditional medicine, Biyeom-Tang on mast cells and allergic rhinitis. *BMCMed Complement. Altern. Med.* 2014, 14, 54. [CrossRef]

120. Na, H.J.; Jeong, H.J.; Hong, S.H.; Hwang, C.Y.; Cha, W.S.; Kim, H.M. Effect of Booy Yong-Tang on Mast Cell-Mediated Allergic Reaction. *Immunopharmacol. Immunotoxicol.* 2004, 26, 445–454. [CrossRef]

121. Shin, S. In vitro effects of essential oils from *Ostericum koreanum* against antibiotic-resistant *Salmonella* spp. *Arch. Pharmacal Res.* 1991, 14, 87. [CrossRef]

122. Xi, W.; Wu, L.; Su, H.; Han, B.; Liu, H.; Xiao, X.; Fan, Y.; Zhang, L.; Huang, Y.; et al. Biyuanshuang suppresses the tolue-2, 4-disocyanate induced allergic rhinitis in guinea pigs. *Oncotarget* 2018, 9, 12620–12629. [CrossRef]

123. Yoon, J.; Lee, S.; Kim, H.; Kim, J.; Park, Y.K. Antiallergic effect of KOBO3, a polyherbal medicine, on mast cell-mediated allergic responses in ovalbumin-induced allergic rhinitis mouse and human mast cells. *J. Ethnopharmacol.* 2012, 142, 684–693. [CrossRef]

124. Jung, H.W.; Jung, J.K.; Park, Y.K. Comparison of the efficacy of KOBO3, ketotifen, and montelukast in an experimental mouse model of allergic rhinitis. *Int. Immunopharmacol.* 2013, 16, 254–260. [CrossRef]

125. Oh, H.A.; Kim, H.M.; Jeong, H.J. Alleviation of allergic rhinitis symptoms with Pyeongwee-San extract (KMP6). *Immunopharmacol. Immunotoxicol.* 2012, 34, 135–142. [CrossRef] [PubMed]
126. Fu, Y.; Kong, Y.; Li, J.; Wang, Y.; Li, M.; Wang, Y.; Ren, F.; Ni, J.; Li, Y.; et al. Mesenchymal stem cells combined with traditional Chinese medicine (qi-fang-bi-min-tang) alleviates rodent allergic rhinitis. *J. Cell. Biochem.* 2019, 127, 123–131. [CrossRef] [PubMed]

127. Ku, J.M.; Hong, S.H.; Kim, S.R.; Choi, H.S.; Seo, H.S.; Jang, B.H.; Ko, S.G.; Shin, Y.C. Anti-allergic effects of So-Cheong-Ryong-Tang in ovalbumin-induced allergic rhinitis model. *Eur. Arch. Otorhinolaryngol.* 2016, 273, 923–930. [CrossRef] [PubMed]

128. Mo, J.H.; Lee, S.E.; Wee, J.H.; Lee, J.E.; Rhee, C.S.; Lee, C.H.; Kim, D.Y. Anti-allergic effects of So-Cheong-Ryong-Tang, a traditional Korean herbal medicine, in an allergic rhinitis mouse model. *Eur. Arch. Otorhinolaryngol.* 2013, 270, 923–930. [CrossRef] [PubMed]

129. Xu, Y.Y.; Liu, X.; Dai, L.B.; Zhou, S.H. Effect of Tong Qiao drops on the expression of eotaxin, IL-13 in the nasal mucosa of rats with allergic rhinitis. *J. Chin. Med. Assoc.* 2012, 75, 524–529. [CrossRef] [PubMed]

130. Ai, S.; Zheng, J.; Chu, K.D.; Zhang, H.S. Effects of Xingbi gel on leukotriene E4 and immunoglobulin E production and nasal eosinophilia in a guinea pig model for allergic rhinitis. *Asian Pac. J. Allergy Immunol.* 2015, 33, 99–106. [CrossRef] [PubMed]

131. Shi, J.; Liu, Y.; Yan, S.; Yan, D. Yiqi Wenyang Fang ameliorates allergic rhinitis through inhibiting inflammatory response and promoting the expression of Foxp3. *Int. J. Immunopathol. Pharm.* 2016, 29, 696–706. [CrossRef] [PubMed]

132. Principal Investigator: Pedro Guardia, D.H.V.; Principal Investigator: Joaquín Quiralte, D.H.V.D.R.; Principal Investigator: Luis Angel Navarro, D.H.L.A.; Principal Investigator: Santiago Nevot, D.H.M. Safety Clinical Trial with Depigopid 50% Grasses/50% Olea Europaea (2000 dpp/mL) or depiGoid 50% Grasses/50% Parietaria Judaica (2000 dpp/mL). Available online: https://www.clinicaltrials.gov/ct2/show/NCT01734265?term=NCT01734265&draw=2&rank=1 (accessed on 29 January 2020).

133. Merck Sharp & Dohme Corp. Safety Study of mk-3641 and mk-7243 Co-Administered in Adult Participants with Ragweed and Grass Pollen Induced Allergic Rhinitis (p08607, mk-3641-006). Available online: https://www.clinicaltrials.gov/ct2/show/NCT02256553?term=NCT02256553&draw=2&rank=1 (accessed on 3 March 2020).

134. Merck Sharp & Dohme Corp. Efficacy and Safety Study of Ragwitek™ (mk-3641) in Children with Ragweed-Induced Rhinoconjunctivitis with or without Asthma (mk-3641-008). Available online: https://www.clinicaltrials.gov/ct2/show/NCT02478398?term=NCT02478398&draw=2&rank=1 (accessed on 6 September 2019).

135. Pfaar, O.; van Twuijver, E.; Boot, J.D.; Opstelten, D.J.; Klimek, L.; van Ree, R.; Diamant, Z.; Kuna, P.; Panzner, P. A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: Results of a phase II study. *Allergy* 2016, 71, 99–107. [CrossRef]

136. Study Chair: Walter G. Canonica, P.D.A.a.R.D.U.o.G. Sublivac Fix Phleum Pratense dt/drf. Available online: https://www.clinicaltrials.gov/ct2/show/NCT01682070?term=NCT01682070&draw=1&rank=1 (accessed on 13 September 2019).

137. Principal Investigator: Peter Couroux, M.I. Efficacy and Safety of Sublivac Phleum for Immunotherapy of Grass Pollen-Allergy. Available online: https://www.clinicaltrials.gov/ct2/show/NCT02556801?term=NCT02556801&draw=1&rank=1 (accessed on 13 September 2019).

138. Wood, R.A.; Tgias, A.; Wildfire, J.; Visness, C.M.; Matsui, E.C.; Gruchalla, R.; Hershey, G.; Liu, A.H.; O’Connor, G.T.; Pongracic, J.A.; et al. Development of cockroach immunotherapy by the Inner-City Asthma Consortium. *J. Allergy Clin. Immunol.* 2014, 133, 846–852.e6. [CrossRef]

139. Study Chair: Robert Wood, M.D.J.H.C.s.C.O.D.o.A.I. Subcutaneous Immunotherapy for Mouse in Adults (Scitmo). Available online: https://www.clinicaltrials.gov/ct2/show/NCT02532179?term=NCT02532179&draw=1&rank=1 (accessed on 7 March 2020).

140. Iwasaki, M.; Saito, K.; Takemura, M.; Sekikawa, K.; Fuji, H.; Yamada, Y.; Wada, H.; Mizuta, K.; Seishima, M.; Ito, Y. TNF-α contributes to the development of allergic rhinitis in mice. *J. Allergy Clin. Immunol.* 2003, 112, 134–140. [CrossRef]

141. Jung, H.W.; Jung, J.K.; Kim, Y.H.; Kang, J.S.; Park, Y.K. Effect of KOB03, a polyherbal medicine, on ovalbumin-induced allergic rhinitis in guinea pigs. *Chin. Med. 2012, 7, 27.* [CrossRef]

142. Tanaka, K.-I.; Okamoto, Y.; Nagaya, Y.; Nishimura, F.; Takeoka, A.; Hanada, S.; Kohno, S.; Kawai, M. A nasal allergy model developed in the guinea pig by intranasal application of 2, 4-toluene diisocyanate. *Int. Arch. Allergy Immunol.* 1988, 85, 392–397. [CrossRef]